Document:

Exhibit 10.1

 

NEUROBO PHARMACEUTICALS, INC.

2022 EQUITY INCENTIVE PLAN

 

ADOPTED BY THE BOARD OF DIRECTORS: November 8, 2022

APPROVED BY THE STOCKHOLDERS: December 22, 2022

 

1.             GENERAL.

 

(a)            Successor
to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date,
(i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve plus any Returning
Shares will become available for issuance pursuant to Awards granted under this Plan; and (iii) all outstanding awards granted under
the Prior Plan will remain subject to the terms of the Prior Plan (except to the extent such outstanding awards result in Returning Shares
that become available for issuance pursuant to Awards granted under this Plan). All Awards granted under this Plan will be subject to
the terms of this Plan.

 

(b)            Plan
Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants,
to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means
by which such persons may be given an opportunity to benefit from increases in value of the Common Stock through the granting of Awards.

 

(c)            Available
Awards. The Plan provides for the grant of the following Awards: (i) Incentive Stock Options; (ii) Nonstatutory Stock
Options; (iii) SARs; (iv) Restricted Stock Awards; (v) RSU Awards; (vi) Performance Awards; and (vii) Other Awards.

 

(d)            Adoption
Date; Effective Date. The Plan will come into existence on the Adoption Date, but no Award may be granted prior to the Effective
Date.

 

2.             SHARES
SUBJECT TO THE PLAN.

 

(a)            Share
Reserve. Subject to adjustment in accordance with Section 2(c) and any adjustments as necessary to implement
any Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed the
sum of (i) 4,910,073 shares, plus (ii) the Prior Plan’s Available Reserve, plus (iii) the number of Returning Shares,
if any, as such shares become available from time to time. In addition, subject to any adjustments as necessary to implement any Capitalization
Adjustments, such aggregate number of shares of Common Stock will automatically increase on January 1st of each year for a period
of five years commencing on January 1, 2023 and ending on (and including) January 1, 2027, to an amount equal to 5% of the Fully
Diluted Shares as of the last day of the preceding calendar year; provided, however that the Board may act prior to the effective date
of any such annual increase to provide that the increase for such year will be a lesser number of shares of Common Stock.

 

(b)            Aggregate
Incentive Stock Option Limit. Notwithstanding anything to the contrary in Section 2(a) and subject to any adjustments
as necessary to implement any Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant
to the exercise of Incentive Stock Options is 15,000,000 shares.

 

     

     

    

 

(c)            Share
Reserve Operation.

 

(i)            Limit
Applies to Common Stock Issued Pursuant to Awards. For clarity, the Share Reserve is a limit on the number of shares of Common
Stock that may be issued pursuant to Awards and does not limit the granting of Awards, except that the Company will keep available at
all times the number of shares of Common Stock reasonably required to satisfy its obligations to issue shares pursuant to such Awards.
Shares may be issued in connection with a merger or acquisition as permitted by, as applicable, Nasdaq Listing Rule 5635(c), NYSE
Listed Company Manual Section 303A.08, NYSE American Company Guide Section 711 or other applicable rule, and such issuance will
not reduce the number of shares available for issuance under the Plan.

 

(ii)            Actions
that Do Not Constitute Issuance of Common Stock and Do Not Reduce Share Reserve. The following actions do not result in an
issuance of shares under the Plan and accordingly do not reduce the number of shares subject to the Share Reserve and available for issuance
under the Plan: (1) the expiration or termination of any portion of an Award without the shares covered by such portion of the Award
having been issued; (2) the settlement of any portion of an Award in cash (i.e., the Participant receives cash rather than
Common Stock); (3) the withholding of shares that would otherwise be issued by the Company to satisfy the exercise, strike or purchase
price of an Award; or (4) the withholding of shares that would otherwise be issued by the Company to satisfy a tax withholding obligation
in connection with an Award.

 

(iii)            Reversion
of Previously Issued Shares of Common Stock to Share Reserve. The following shares of Common Stock previously issued pursuant
to an Award and accordingly initially deducted from the Share Reserve will be added back to the Share Reserve and again become available
for issuance under the Plan: (1) any shares that are forfeited back to or repurchased by the Company because of a failure to meet
a contingency or condition required for the vesting of such shares; (2) any shares that are reacquired by the Company to satisfy
the exercise, strike or purchase price of an Award; and (3) any shares that are reacquired by the Company to satisfy a tax withholding
obligation in connection with an Award.

 

3.             ELIGIBILITY
AND LIMITATIONS.

 

(a)            Eligible
Award Recipients. Subject to the terms of the Plan, Employees, Directors and Consultants are eligible to receive Awards.

 

(b)            Specific
Award Limitations.

 

(i)            Limitations
on Incentive Stock Option Recipients. Incentive Stock Options may be granted only to Employees of the Company or a “parent
corporation” or “subsidiary corporation” thereof (as such terms are defined in Sections 424(e) and (f) of
the Code).

 

(ii)            Incentive
Stock Option $100,000 Limitation. To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common
Stock with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under
all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not comply
with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the order
in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding
any contrary provision of the applicable Option Agreement(s).

 

     

     

    

 

(iii)            Limitations
on Incentive Stock Options Granted to Ten Percent Stockholders. A Ten Percent Stockholder may not be granted an Incentive Stock
Option unless (i) the exercise price of such Option is at least 110% of the Fair Market Value on the date of grant of such Option
and (ii) the Option is not exercisable after the expiration of five years from the date of grant of such Option.

 

(iv)            Limitations
on Nonstatutory Stock Options and SARs. Nonstatutory Stock Options and SARs may not be granted to Employees, Directors and
Consultants who are providing Continuous Service only to any “parent” of the Company (as such term is defined in Rule 405)
unless the stock underlying such Awards is treated as “service recipient stock” under Section 409A because the Awards
are granted pursuant to a corporate transaction (such as a spin off transaction) or unless such Awards otherwise comply with the distribution
requirements of Section 409A.

 

(c)            Aggregate
Incentive Stock Option Limit. The aggregate maximum number of shares of the Common Stock that may be issued pursuant to the
exercise of Incentive Stock Options is the number of shares specified in Section 2(b).

 

(d)            Non-Employee
Director Compensation Limit. The aggregate value of all compensation granted or paid, as applicable, to any individual for
service as a Non-Employee Director with respect to any calendar year, including Awards granted and cash fees paid by the Company to such
Non-Employee Director, will not exceed (i) $750,000 in total value or (ii) in the event such Non-Employee Director is first
appointed or elected to the Board during such calendar year, $1,000,000 in total value, in each case calculating the value of any equity
awards based on the grant date fair value of such equity awards for financial reporting purposes. The limitations in this Section 3(d) shall
apply beginning with the first calendar year that commences following the Effective Date.

 

4.            OPTIONS
AND STOCK APPRECIATION RIGHTS.

 

Each Option and SAR will have
such terms and conditions as determined by the Board. Each Option will be designated in writing as an Incentive Stock Option or Nonstatutory
Stock Option at the time of grant; provided, however, that if an Option is not so designated, then such Option will be a Nonstatutory
Stock Option. The shares purchased upon exercise of each type of Option will be accounted for separately. Each SAR will be denominated
in shares of the Common Stock equivalents. The terms and conditions of separate Options and SARs need not be identical; provided, however,
that each Option Agreement and SAR Agreement will conform (through incorporation of provisions hereof by reference in the Award Agreement
or otherwise) to the substance of each of the following provisions:

 

(a)            Term.
Subject to Section 3(b) regarding Incentive Stock Options granted to Ten Percent Stockholders, no Option or SAR will
be exercisable after the expiration of ten years from the date of grant of such Award or such shorter period specified in the Award Agreement.

 

(b)            Exercise
or Strike Price. Subject to Section 3(b) regarding Ten Percent Stockholders, the exercise or strike price
of each Option or SAR will not be less than 100% of the Fair Market Value on the date of grant of such Award. Notwithstanding the foregoing,
an Option or SAR may be granted with an exercise or strike price lower than 100% of the Fair Market Value on the date of grant of such
Award if such Award is granted pursuant to an assumption of or substitution for another option or stock appreciation right pursuant to
a Corporate Transaction and in a manner consistent with the provisions of Sections 409A and, if applicable, 424(a) of the Code.

 

     

     

    

 

(c)            Exercise
Procedure and Payment of Exercise Price for Options. In order to exercise an Option, the Participant must provide notice of
exercise to the Plan Administrator in accordance with the procedures specified in the Option Agreement or otherwise provided by the Company.
The Board has the authority to grant Options that do not permit all of the following methods of payment (or otherwise restrict the ability
to use certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. The exercise
price of an Option may be paid, to the extent permitted by Applicable Law and as determined by the Board, by one or more of the following
methods of payment to the extent set forth in the Option Agreement:

 

(i)            by
cash or check, wire, bank draft or money order (or an electronic equivalent thereof) payable to the Company;

 

(ii)            pursuant
to a “cashless exercise” program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the
issuance of the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of
irrevocable instructions to pay the exercise price to the Company from the sales proceeds;

 

(iii)           by
delivery to the Company (either by actual delivery or attestation) of shares of Common Stock that are already owned by the Participant
free and clear of any liens, claims, encumbrances or security interests, with a Fair Market Value on the date of exercise that does not
exceed the exercise price, provided that (1) at the time of exercise the Common Stock is publicly traded, (2) any remaining
balance of the exercise price not satisfied by such delivery is paid by the Participant in cash or other permitted form of payment, (3) such
delivery would not violate any Applicable Law or agreement restricting the redemption of the Common Stock, (4) any certificated shares
are endorsed or accompanied by an executed assignment separate from certificate, and (5) such shares have been held by the Participant
for any minimum period necessary to avoid adverse accounting treatment as a result of such delivery;

 

(iv)           by
a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issuable upon
exercise by the largest whole number of shares with a Fair Market Value on the date of exercise that does not exceed the exercise price,
provided that (1) such shares used to pay the exercise price will not be exercisable thereafter and (2) any remaining balance
of the exercise price not satisfied by such net exercise is paid by the Participant in cash or other permitted form of payment; or

 

(v)            in
any other form of consideration that may be acceptable to the Board and permissible under Applicable Law.

 

(d)            Exercise
Procedure and Payment of Appreciation Distribution for SARs. In order to exercise any SAR, the Participant must provide notice
of exercise to the Plan Administrator in accordance with the SAR Agreement. The appreciation distribution payable to a Participant upon
the exercise of a SAR will not be greater than an amount equal to the excess of (i) the aggregate Fair Market Value on the date of
exercise of a number of shares of the Common Stock equal to the number of the Common Stock equivalents that are vested and being exercised
under such SAR, over (ii) the strike price of such SAR. Such appreciation distribution may be paid to the Participant in the form
of the Common Stock or cash (or any combination of the Common Stock and cash) or in any other form of payment, as determined by the Board
and specified in the SAR Agreement.

 

(e)            Transferability.
Options and SARs may not be transferred to third party financial institutions for value. The Board may impose such additional limitations
on the transferability of an Option or SAR as it determines. In the absence of any such determination by the Board, the following restrictions
on the transferability of Options and SARs will apply, provided that except as explicitly provided herein, neither an Option nor a SAR
may be transferred for consideration and provided, further, that if an Option is an Incentive Stock Option, such Option may be
deemed to be a Nonstatutory Stock Option as a result of such transfer:

 

(i)            Restrictions
on Transfer. An Option or SAR will not be transferable, except by will or by the laws of descent and distribution, and will
be exercisable during the lifetime of the Participant only by the Participant; provided, however, that the Board may permit transfer of
an Option or SAR in a manner that is not prohibited by applicable tax and securities laws upon the Participant’s request, including
to a trust if the Participant is considered to be the sole beneficial owner of such trust (as determined under Section 671 of the
Code and applicable state law) while such Option or SAR is held in such trust, provided that the Participant and the trustee enter into
a transfer and other agreements required by the Company.

 

     

     

    

 

(ii)            Domestic
Relations Orders. Notwithstanding the foregoing, subject to the execution of transfer documentation in a format acceptable
to the Company and subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant to
a domestic relations order.

 

(f)            Vesting.
The Board may impose such restrictions on or conditions to the vesting and/or exercisability of an Option or SAR as determined by the
Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or an Affiliate,
vesting of Options and SARs will cease upon termination of the Participant’s Continuous Service.

 

(g)            Termination
of Continuous Service for Cause. Except as explicitly otherwise provided in the Award Agreement or other written agreement
between a Participant and the Company or an Affiliate, if a Participant’s Continuous Service is terminated for Cause, the Participant’s
Options and SARs will terminate and be forfeited immediately upon such termination of Continuous Service, and the Participant will be
prohibited from exercising any portion (including any vested portion) of such Awards on and after the date of such termination of Continuous
Service and the Participant will have no further right, title or interest in such forfeited Award, the shares of Common Stock subject
to the forfeited Award, or any consideration in respect of the forfeited Award.

 

(h)            Post-Termination
Exercise Period Following Termination of Continuous Service for Reasons Other than Cause. Subject to Section 4(i),
if a Participant’s Continuous Service terminates for any reason other than for Cause, the Participant may exercise their Option
or SAR to the extent vested, but only within the following period of time or, if applicable, such other period of time provided in the
Award Agreement or other written agreement between a Participant and the Company or an Affiliate; provided, however, that in no event
may such Award be exercised after the expiration of its maximum term (as set forth in Section 4(a)):

 

(i)            three
months following the date of such termination if such termination is a termination without Cause (other than any termination due to the
Participant’s Disability or death);

 

(ii)           12
months following the date of such termination if such termination is due to the Participant’s Disability;

 

(iii)          18
months following the date of such termination if such termination is due to the Participant’s death; or

 

(iv)           18
months following the date of the Participant’s death if such death occurs following the date of such termination but during the
period such Award is otherwise exercisable (as provided in (i) or (ii) above).

 

     

     

    

 

Following the date of such
termination, to the extent the Participant does not exercise such Award within the applicable Post-Termination Exercise Period (or, if
earlier, prior to the expiration of the maximum term of such Award), such unexercised portion of the Award will terminate, and the Participant
will have no further right, title or interest in the terminated Award, the shares of Common Stock subject to the terminated Award, or
any consideration in respect of the terminated Award.

 

(i)            Restrictions
on Exercise; Extension of Exercisability. A Participant may not exercise an Option or SAR at any time that the issuance of
shares of Common Stock upon such exercise would violate Applicable Law. Except as otherwise provided in the Award Agreement or other written
agreement between a Participant and the Company or an Affiliate, if a Participant’s Continuous Service terminates for any reason
other than for Cause and, at any time during the last thirty days of the applicable Post-Termination Exercise Period: (i) the exercise
of the Participant’s Option or SAR would be prohibited solely because the issuance of shares of Common Stock upon such exercise
would violate Applicable Law, or (ii) the immediate sale of any shares of Common Stock issued upon such exercise would violate the
Company’s Trading Policy, then the applicable Post-Termination Exercise Period will be extended to the last day of the calendar
month that commences following the date the Award would otherwise expire, with an additional extension of the exercise period to the last
day of the next calendar month to apply if any of the foregoing restrictions apply at any time during such extended exercise period, generally
without limitation as to the maximum permitted number of extensions; provided, however, that in no event may such Award be exercised after
the expiration of its maximum term (as set forth in Section 4(a)).

 

(j)            Non-Exempt
Employees. No Option or SAR, whether or not vested, granted to an Employee who is a non-exempt employee for purposes of the
Fair Labor Standards Act of 1938, as amended, will be first exercisable for any shares of Common Stock until at least six months following
the date of grant of such Award. Notwithstanding the foregoing, in accordance with the provisions of the Worker Economic Opportunity Act,
any vested portion of such Award may be exercised earlier than six months following the date of grant of such Award in the event of (i) such
Participant’s death or Disability, (ii) a Corporate Transaction in which such Award is not assumed, continued or substituted,
(iii) a Change in Control, or (iv) such Participant’s retirement (as such term may be defined in the Award Agreement or
another applicable agreement or, in the absence of any such definition, in accordance with the Company’s then current employment
policies and guidelines). This Section 4(j) is intended to operate so that any income derived by a non-exempt employee
in connection with the exercise or vesting of an Option or SAR will be exempt from their regular rate of pay.

 

(k)            Whole
Shares. Options and SARs may be exercised only with respect to whole shares of the Common Stock or their equivalents.

 

5.             AWARDS
OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS.

 

(a)            Restricted
Stock Awards and RSU Awards. Each Restricted Stock Award and RSU Award will have such terms and conditions as determined by
the Board; provided, however, that each Restricted Stock Award Agreement and RSU Award Agreement will conform (through incorporation of
the provisions hereof by reference in the Award Agreement or otherwise) to the substance of each of the following provisions:

 

(i)             Form of
Award.

 

(1)            RSAs.
To the extent consistent with the Company’s Bylaws, at the Board’s election, shares of the Common Stock subject to a Restricted
Stock Award may be (A) held in book entry form subject to the Company’s instructions until such shares become vested or any
other restrictions lapse, or (B) evidenced by a certificate, which certificate will be held in such form and manner as determined
by the Board. Unless otherwise determined by the Board, a Participant will have voting and other rights as a stockholder of the Company
with respect to any shares subject to a Restricted Stock Award.

 

     

     

    

 

(2)            RSUs.
An RSU Award represents a Participant’s right to be issued on a future date the number of shares of the Common Stock that is equal
to the number of restricted stock units subject to the RSU Award. As a holder of an RSU Award, a Participant is an unsecured creditor
of the Company with respect to the Company’s unfunded obligation, if any, to issue shares of the Common Stock in settlement of such
Award and nothing contained in the Plan or any RSU Agreement, and no action taken pursuant to its provisions, will create or be construed
to create a trust of any kind or a fiduciary relationship between a Participant and the Company or an Affiliate or any other person. A
Participant will not have voting or any other rights as a stockholder of the Company with respect to any RSU Award (unless and until shares
are actually issued in settlement of a vested RSU Award).

 

(ii)           Consideration.

 

(1)            RSA.
A Restricted Stock Award may be granted in consideration for (A) cash or check, wire, bank draft or money order payable to the Company,
(B) past services to the Company or an Affiliate, or (C) any other form of consideration (including future services)as the Board
may determine and permissible under Applicable Law.

 

(2)            RSU.
Unless otherwise determined by the Board at the time of grant, an RSU Award will be granted in consideration for the Participant’s
services to the Company or an Affiliate, such that the Participant will not be required to make any payment to the Company (other than
such services) with respect to the grant or vesting of the RSU Award, or the issuance of any shares of the Common Stock pursuant to the
RSU Award. If, at the time of grant, the Board determines that any consideration must be paid by the Participant (in a form other than
the Participant’s services to the Company or an Affiliate) upon the issuance of any shares of the Common Stock in settlement of
the RSU Award, such consideration may be paid in any form of consideration as the Board may determine and permissible under Applicable
Law.

 

(iii)          Vesting.
The Board may impose such restrictions on or conditions to the vesting of a Restricted Stock Award or RSU Award as determined
by the Board. Except as otherwise provided in the Award Agreement or other written agreement between a Participant and the Company or
an Affiliate, vesting of Restricted Stock Awards and RSU Awards will cease upon termination of the Participant’s Continuous Service.

 

(iv)           Termination
of Continuous Service. Except as otherwise provided in the Award Agreement or other written agreement between a Participant
and the Company or an Affiliate, if a Participant’s Continuous Service terminates for any reason, (1) the Company may receive
through a forfeiture condition or a repurchase right any or all of the shares of the Common Stock held by the Participant under their
Restricted Stock Award that have not vested as of the date of such termination as set forth in the Restricted Stock Award Agreement and
(2) any portion of their RSU Award that has not vested will be forfeited upon such termination and the Participant will have no further
right, title or interest in the RSU Award, the shares of the Common Stock issuable pursuant to the RSU Award, or any consideration in
respect of the RSU Award.

 

(v)            Dividends
and Dividend Equivalents. Dividends or dividend equivalents may be paid or credited, as applicable, with respect to any shares
of the Common Stock subject to a Restricted Stock Award or RSU Award, as determined by the Board and specified in the Award Agreement).

 

     

     

    

 

(vi)            Settlement
of RSU Awards. An RSU Award may be settled by the issuance of shares of the Common Stock or cash (or any combination thereof)
or in any other form of payment, as determined by the Board and specified in the RSU Award Agreement. At the time of grant, the Board
may determine to impose such restrictions or conditions that delay such delivery to a date following the vesting of the RSU Award.

 

(b)            Performance
Awards. With respect to any Performance Award, the length of any Performance Period, the Performance Goals to be achieved during
the Performance Period, the other terms and conditions of such Award, and the measure of whether and to what degree such Performance Goals
have been attained will be determined by the Board.

 

(c)            Other
Awards. Other forms of Awards valued in whole or in part by reference to, or otherwise based on, the Common Stock, including
the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market
Value at the time of grant) may be granted either alone or in addition to Awards provided for under Section 4 and the preceding
provisions of this Section 5. Subject to the provisions of the Plan, the Board will have sole and complete discretion to determine
the persons to whom and the time or times at which such Other Awards will be granted, the number of shares of the Common Stock (or the
cash equivalent thereof) to be granted pursuant to such Other Awards and all other terms and conditions of such Other Awards.

 

6.             ADJUSTMENTS
UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS.

 

(a)            Capitalization
Adjustments. In the event of a Capitalization Adjustment, the Board shall appropriately and proportionately adjust: (i) the
class(es) and maximum number of shares of the Common Stock subject to the Plan and the maximum number of shares by which the Share Reserve
may annually increase pursuant to Section 2(a); (ii) the class(es) and maximum number of shares that may be issued pursuant
to the exercise of Incentive Stock Options pursuant to Section 2(b); and (iii) the class(es) and number of securities
and exercise price, strike price or purchase price of the Common Stock subject to outstanding Awards. The Board shall make such adjustments,
and its determination shall be final, binding and conclusive. Notwithstanding the foregoing, no fractional shares or rights for fractional
shares of the Common Stock shall be created in order to implement any Capitalization Adjustment. The Board shall determine an appropriate
equivalent benefit, if any, for any fractional shares or rights to fractional shares that might be created by the adjustments referred
to in the preceding provisions of this Section 6.

 

(b)            Dissolution
or Liquidation. Except as otherwise provided in the Award Agreement, in the event of a dissolution or liquidation of the Company,
all outstanding Awards (other than Awards consisting of vested and outstanding shares of the Common Stock not subject to a forfeiture
condition or the Company’s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation,
and the shares of the Common Stock subject to the Company’s repurchase rights or subject to a forfeiture condition may be repurchased
or reacquired by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service; provided, however,
that the Board may determine to cause some or all Awards to become fully vested, exercisable and/or no longer subject to repurchase or
forfeiture (to the extent such Awards have not previously expired or terminated) before the dissolution or liquidation is completed but
contingent on its completion.

 

     

     

    

 

(c)            Corporate
Transaction. The following provisions will apply to Awards in the event of a Corporate Transaction, except as set forth in
Section 11, unless otherwise provided in the instrument evidencing the Award or any other written agreement between the Company
or any Affiliate and the Participant or unless otherwise expressly provided by the Board at the time of grant of an Award.

 

(i)            Awards
May Be Assumed. In the event of a Corporate Transaction, any surviving or acquiring corporation (or the surviving or acquiring
corporation’s parent company) may assume or continue any or all Awards outstanding under the Plan or may substitute similar awards
for Awards outstanding under the Plan (including but not limited to awards to acquire the same consideration paid to the stockholders
of the Company pursuant to the Corporate Transaction), and any reacquisition or repurchase rights held by the Company in respect of the
Common Stock issued pursuant to Awards may be assigned by the Company to the successor of the Company (or the successor’s parent
company, if any), in connection with such Corporate Transaction. A surviving or acquiring corporation (or its applicable parent) may choose
to assume or continue only a portion of an Award or substitute a similar award for only a portion of an Award, or may choose to assume
or continue the Awards held by some, but not all Participants. The terms of any assumption, continuation or substitution will be set by
the Board.

 

(ii)            Awards
Held by Current Participants. In the event of a Corporate Transaction in which the surviving or acquiring corporation (or its
parent company) does not assume or continue outstanding Awards or substitute similar awards for such outstanding Awards, then with respect
to Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated
prior to the effective time of the Corporate Transaction (referred to as the “Current Participants”), the vesting
of such Awards (and, with respect to Options and Stock Appreciation Rights, the time when such Awards may be exercised) will be accelerated
in full to a date prior to the effective time of such Corporate Transaction (contingent upon the effectiveness of the Corporate Transaction)
that the Board determines (or, if the Board does not determine such a date, to the date that is five (5) days prior to the effective
time of the Corporate Transaction). Awards so accelerated will terminate if not exercised (if applicable) at or prior to the effective
time of the Corporate Transaction, and any reacquisition or repurchase rights held by the Company with respect to such Awards will lapse
(contingent upon the effectiveness of the Corporate Transaction). With respect to the vesting of Performance Awards that (a) will
accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii) and (b) have multiple vesting levels
depending on the level of performance, unless otherwise provided in the Award Agreement or unless otherwise provided by the Board, the
vesting of such Performance Awards will accelerate at 100% of the target level upon the occurrence of a Corporate Transaction in which
the Awards are not assumed, continued or substituted for in accordance with Section 6(c)(i). With respect to the vesting of
cash-settled Awards that will accelerate upon the occurrence of a Corporate Transaction pursuant to this subsection (ii), such cash payment
will be made no later than 30 days following the occurrence of the Corporate Transaction or such later date as required by Section 409A
of the Code.

 

(iii)            Awards
Held by Persons other than Current Participants. In the event of a Corporate Transaction in which the surviving or acquiring
corporation (or its parent company) does not assume or continue such outstanding Awards or substitute similar awards for such outstanding
Awards, then with respect to Awards that have not been assumed, continued or substituted and that are held by persons other than Current
Participants, such Awards will terminate if not exercised (if applicable) prior to the occurrence of the Corporate Transaction; provided,
however, that any reacquisition or repurchase rights held by the Company with respect to such Awards will not terminate and may continue
to be exercised notwithstanding the Corporate Transaction.

 

     

     

    

 

(iv)            Payment
for Awards in Lieu of Exercise. Notwithstanding the foregoing, in the event an Award will terminate if not exercised prior
to the effective time of a Corporate Transaction, the Board may provide, in its sole discretion, that the holder of such Award may not
exercise such Award but will receive a payment, in such form as may be determined by the Board, equal in value, at the effective time,
to the excess, if any, of (1) the value of the property the Participant would have received upon the exercise of the Award (including,
at the discretion of the Board, any unvested portion of such Award), over (2) any exercise price payable by such holder in connection
with such exercise.

 

(d)            Appointment
of Stockholder Representative. As a condition to the receipt of an Award under this Plan, a Participant will be deemed to have
agreed that the Award will be subject to the terms of any agreement governing a Corporate Transaction involving the Company, including,
without limitation, a provision for the appointment of a stockholder representative that is authorized to act on the Participant’s
behalf with respect to any escrow, indemnities and any contingent consideration.

 

(e)            No
Restriction on Right to Undertake Transactions. The grant of any Award under the Plan and the issuance of shares pursuant to
any Award does not affect or restrict in any way the right or power of the Company or the stockholders of the Company to make or authorize
any adjustment, recapitalization, reorganization or other change in the Company’s capital structure or its business, any merger
or consolidation of the Company, any issue of stock or of options, rights or options to purchase stock or of bonds, debentures, preferred
or prior preference stocks whose rights are superior to or affect the Common Stock or the rights thereof or which are convertible into
or exchangeable for the Common Stock, or the dissolution or liquidation of the Company, or any sale or transfer of all or any part of
its assets or business, or any other corporate act or proceeding, whether of a similar character or otherwise.

 

7.             ADMINISTRATION.

 

(a)            Administration
by Board. The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee
or Committees, as provided in subsection (c) below.

 

(b)            Powers
of Board. The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:

 

(i)            To
determine from time to time (1) which of the persons eligible under the Plan will be granted Awards; (2) when and how each Award
will be granted; (3) what type or combination of types of Award will be granted; (4) the provisions of each Award granted (which
need not be identical), including the time or times when a person will be permitted to receive an issuance of the Common Stock or other
payment pursuant to an Award; (5) the number of shares of the Common Stock or cash equivalent with respect to which an Award will
be granted to each such person; (6) the Fair Market Value applicable to an Award; and (7) the terms of any Performance Award
that is not valued in whole or in part by reference to, or otherwise based on, the Common Stock, including the amount of cash payment
or other property that may be earned and the timing of payment.

 

(ii)            To
construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for its administration.
The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Award Agreement, in
a manner and to the extent it deems necessary or expedient to make the Plan or Award fully effective.

 

(iii)            To
settle all controversies regarding the Plan and Awards granted under it.

 

     

     

    

 

(iv)            To
accelerate the time at which an Award may first be exercised or the time during which an Award or any part thereof will vest, notwithstanding
the provisions in the Award Agreement stating the time at which it may first be exercised or the time during which it will vest.

 

(v)              To
prohibit the exercise of any Option, SAR or other exercisable Award during a period of up to 30 days prior to the consummation of any
pending stock dividend, stock split, combination or exchange of shares, merger, consolidation or other distribution (other than normal
cash dividends) of Company assets to stockholders, or any other change affecting the shares of the Common Stock or the share price of
the Common Stock including any Corporate Transaction, for reasons of administrative convenience.

 

(vi)            To
suspend or terminate the Plan at any time. Suspension or termination of the Plan will not Materially Impair rights and obligations under
any Award granted while the Plan is in effect except with the written consent of the affected Participant.

 

(vii)           To
amend the Plan in any respect the Board deems necessary or advisable; provided, however, that stockholder approval will be required
for any amendment to the extent required by Applicable Law. Except as provided above, rights under any Award granted before amendment
of the Plan will not be Materially Impaired by any amendment of the Plan unless (1) the Company requests the consent of the affected
Participant, and (2) such Participant consents in writing.

 

(viii)         To
submit any amendment to the Plan for stockholder approval.

 

(ix)            To
approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited
to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any specified
limits in the Plan that are not subject to Board discretion; provided however, that, a Participant’s rights under any Award
will not be Materially Impaired by any such amendment unless (1) the Company requests the consent of the affected Participant, and
(2) such Participant consents in writing.

 

(x)              Generally,
to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the Company
and that are not in conflict with the provisions of the Plan or Awards.

 

(xi)            To
adopt such procedures and sub-plans as are necessary or appropriate to permit and facilitate participation in the Plan by, or take advantage
of specific tax treatment for Awards granted to, Employees, Directors or Consultants who are foreign nationals or employed outside the
United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement to ensure
or facilitate compliance with the laws of the relevant foreign jurisdiction).

 

(xii)            To
effect, at any time and from time to time, subject to the consent of any Participant whose Award is Materially Impaired by such action,
(1) the reduction of the exercise price (or strike price) of any outstanding Option or SAR; (2) the cancellation of any outstanding
Option or SAR and the grant in substitution therefor of (A) a new Option, SAR, Restricted Stock Award, RSU Award or Other Award,
under the Plan or another equity plan of the Company, covering the same or a different number of shares of the Common Stock, (B) cash
and/or (C) other valuable consideration (as determined by the Board); or (3) any other action that is treated as a repricing
under generally accepted accounting principles.

 

     

     

    

 

(c)            Delegation
to Committee.

 

(i)            General.
The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated
to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board
that have been delegated to the Committee, including the power to delegate to another Committee or a subcommittee of the Committee any
of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the
Committee or subcommittee), subject, however, to such resolutions, not inconsistent with the provisions of the Plan, as may be adopted
from time to time by the Board. Each Committee may retain the authority to concurrently administer the Plan with Committee or subcommittee
to which it has delegated its authority hereunder and may, at any time, revest in such Committee some or all of the powers previously
delegated. The Board may retain the authority to concurrently administer the Plan with any Committee and may, at any time, revest in the
Board some or all of the powers previously delegated.

 

(ii)            Rule 16b-3
Compliance. To the extent an Award is intended to qualify for the exemption from Section 16(b) of the Exchange Act
that is available under Rule 16b-3 under the Exchange Act, the Award will be granted by the Board or a Committee that consists solely
of two or more Non-Employee Directors, as determined under Rule 16b-3(b)(3) under the Exchange Act and thereafter any action
establishing or modifying the terms of the Award will be approved by the Board or a Committee meeting such requirements to the extent
necessary for such exemption to remain available.

 

(d)            Effect
of Board’s Decision. All determinations, interpretations and constructions made by the Board or any Committee in good
faith will not be subject to review by any person and will be final, binding and conclusive on all persons.

 

(e)            Delegation
to an Officer. The Board or any Committee may delegate to one or more Officers the authority to do one or both of the following
(i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by Applicable Law,
other types of Awards) and, to the extent permitted by Applicable Law, the terms thereof, and (ii) determine the number of shares
of the Common Stock to be subject to such Awards granted to such Employees; provided, however, that the resolutions or charter adopted
by the Board or any Committee evidencing such delegation will specify the total number of shares of the Common Stock that may be subject
to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted
on the applicable form of Award Agreement most recently approved for use by the Board or the Committee, unless otherwise provided in the
resolutions approving the delegation authority. Notwithstanding anything to the contrary herein, neither the Board nor any Committee may
delegate to an Officer who is acting solely in the capacity of an Officer (and not also as a Director) the authority to determine the
Fair Market Value.

 

8.             TAX
WITHHOLDING.

 

(a)            Withholding
Authorization. As a condition to acceptance of any Award under the Plan, a Participant authorizes withholding from payroll
and any other amounts payable to such Participant, and otherwise agrees to make adequate provision for (including), any sums required
to satisfy any U.S. federal, state, local and/or foreign tax or social insurance contribution withholding obligations of the Company or
an Affiliate, if any, which arise in connection with the exercise, vesting or settlement of such Award, as applicable. Accordingly, a
Participant may not be able to exercise an Award even though the Award is vested, and the Company shall have no obligation to issue shares
of the Common Stock subject to an Award, unless and until such obligations are satisfied.

 

     

     

    

 

(b)            Satisfaction
of Withholding Obligation. To the extent permitted by the terms of an Award Agreement, the Company may, in its sole discretion,
satisfy any U.S. federal, state, local and/or foreign tax or social insurance withholding obligation relating to an Award by any of the
following means or by a combination of such means: (i) causing the Participant to tender a cash payment; (ii) withholding shares
of the Common Stock from the shares of the Common Stock issued or otherwise issuable to the Participant in connection with the Award;
(iii) withholding cash from an Award settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant;
(v) by allowing a Participant to effectuate a “cashless exercise” pursuant to a program developed under Regulation T
as promulgated by the Federal Reserve Board; or (vi) by such other method as may be set forth in the Award Agreement.

 

(c)            No
Obligation to Notify or Minimize Taxes; No Liability to Claims. Except as required by Applicable Law the Company has no duty
or obligation to any Participant to advise such holder as to the time or manner of exercising such Award. Furthermore, the Company has
no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a possible period
in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder
of such Award and will not be liable to any holder of an Award for any adverse tax consequences to such holder in connection with an Award.
As a condition to accepting an Award under the Plan, each Participant (i) agrees to not make any claim against the Company, or any
of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from such Award or other Company compensation and
(ii) acknowledges that such Participant was advised to consult with their own personal tax, financial and other legal advisors regarding
the tax consequences of the Award and has either done so or knowingly and voluntarily declined to do so. Additionally, each Participant
acknowledges any Option or SAR granted under the Plan is exempt from Section 409A only if the exercise or strike price is at least
equal to the “fair market value” of the Common Stock on the date of grant as determined by the Internal Revenue Service and
there is no other impermissible deferral of compensation associated with the Award. Additionally, as a condition to accepting an Option
or SAR granted under the Plan, each Participant agrees not make any claim against the Company, or any of its Officers, Directors, Employees
or Affiliates in the event that the Internal Revenue Service asserts that such exercise price or strike price is less than the “fair
market value” of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.

 

(d)            Withholding
Indemnification. As a condition to accepting an Award under the Plan, in the event that the amount of the Company’s and/or
its Affiliate’s withholding obligation in connection with such Award was greater than the amount actually withheld by the Company
and/or its Affiliates, each Participant agrees to indemnify and hold the Company and/or its Affiliates harmless from any failure by the
Company and/or its Affiliates to withhold the proper amount.

 

9.             MISCELLANEOUS.

 

(a)            Source
of Shares. The stock issuable under the Plan will be shares of authorized but unissued or reacquired shares of the Common Stock,
including shares repurchased by the Company on the open market or otherwise.

 

(b)            Use
of Proceeds from Sales of the Common Stock. Proceeds from the sale of shares of the Common Stock pursuant to Awards will constitute
general funds of the Company.

 

(c)            Corporate
Action Constituting Grant of Awards. Corporate action constituting a grant by the Company of an Award to any Participant will
be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument,
certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event that
the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action approving the grant contain terms
(e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement or related grant
documents as a result of a clerical error in the Award Agreement or related grant documents, the corporate records will control and the
Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents.

 

     

     

    

 

(d)            Stockholder
Rights. No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares
of the Common Stock subject to such Award unless and until (i) such Participant has satisfied all requirements for exercise of the
Award pursuant to its terms, if applicable, and (ii) the issuance of the Common Stock subject to such Award is reflected in the records
of the Company.

 

(e)            No
Employment or Other Service Rights. Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or
in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company or an
Affiliate in the capacity in effect at the time the Award was granted or affect the right of the Company or an Affiliate to terminate
at will and without regard to any future vesting opportunity that a Participant may have with respect to any Award (i) the employment
of an Employee with or without notice and with or without cause, (ii) the service of a Consultant pursuant to the terms of such Consultant’s
agreement with the Company or an Affiliate, or (iii) the service of a Director pursuant to the Bylaws of the Company or an Affiliate,
and any applicable provisions of the corporate law of the state or foreign jurisdiction in which the Company or the Affiliate is incorporated,
as the case may be. Further, nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with
any Award will constitute any promise or commitment by the Company or an Affiliate regarding the fact or nature of future positions, future
work assignments, future compensation or any other term or condition of employment or service or confer any right or benefit under the
Award or the Plan unless such right or benefit has specifically accrued under the terms of the Award Agreement and/or Plan.

 

(f)            Change
in Time Commitment. In the event a Participant’s regular level of time commitment in the performance of their services
for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company and
the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence) after the
date of grant of any Award to the Participant, the Board may determine, to the extent permitted by Applicable Law, to (i) make a
corresponding reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become
payable after the date of such change in time commitment, and (ii) in lieu of or in combination with such a reduction, extend the
vesting or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect
to any portion of the Award that is so reduced or extended.

 

(g)            Execution
of Additional Documents. As a condition to accepting an Award under the Plan, the Participant agrees to execute any additional
documents or instruments necessary or desirable, as determined in the Plan Administrator’s sole discretion, to carry out the purposes
or intent of the Award, or facilitate compliance with securities and/or other regulatory requirements, in each case at the Plan Administrator’s
request.

 

(h)            Electronic
Delivery and Participation. Any reference herein or in an Award Agreement to a “written” agreement or document
will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted
on the Company’s intranet (or other shared electronic medium controlled by the Company to which the Participant has access). By
accepting any Award the Participant consents to receive documents by electronic delivery and to participate in the Plan through any on-line
electronic system established and maintained by the Plan Administrator or another third party selected by the Plan Administrator. The
form of delivery of any the Common Stock (e.g., a stock certificate or electronic entry evidencing such shares) shall be determined by
the Company.

 

     

     

    

 

(i)            Clawback/Recovery.
All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required to
adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities are
listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law and any clawback
policy that the Company otherwise adopts, to the extent applicable and permissible under Applicable Law. In addition, the Board may impose
such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate, including
but not limited to a reacquisition right in respect of previously acquired shares of the Common Stock or other cash or property upon the
occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving rise to a Participant’s right
to voluntarily terminate employment upon a “resignation for good reason,” or for a “constructive termination”
or any similar term under any plan of or agreement with the Company.

 

(j)            Securities
Law Compliance. A Participant will not be issued any shares in respect of an Award unless either (i) the shares are registered
under the Securities Act; or (ii) the Company has determined that such issuance would be exempt from the registration requirements
of the Securities Act. Each Award also must comply with other Applicable Law governing the Award, and a Participant will not receive such
shares if the Company determines that such receipt would not be in material compliance with Applicable Law.

 

(k)           Transfer
or Assignment of Awards; Issued Shares. Except as expressly provided in the Plan or the form of Award Agreement, Awards granted
under the Plan may not be transferred or assigned by the Participant. After the vested shares subject to an Award have been issued, or
in the case of Restricted Stock and similar awards, after the issued shares have vested, the holder of such shares is free to assign,
hypothecate, donate, encumber or otherwise dispose of any interest in such shares provided that any such actions are in compliance with
the provisions herein, the terms of the Trading Policy and Applicable Law.

 

(l)            Effect
on Other Employee Benefit Plans. The value of any Award granted under the Plan, as determined upon grant, vesting or settlement,
shall not be included as compensation, earnings, salaries, or other similar terms used when calculating any Participant’s benefits
under any employee benefit plan sponsored by the Company or any Affiliate, except as such plan otherwise expressly provides. The Company
expressly reserves its rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee benefit plans.

 

(m)          Deferrals.
To the extent permitted by Applicable Law, the Board, in its sole discretion, may determine that the delivery of the Common Stock or the
payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may also establish programs
and procedures for deferral elections to be made by Participants. Deferrals will be made in accordance with the requirements of Section 409A.

 

(n)            Section 409A.
Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements will be interpreted to the greatest
extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section 409A, and, to the extent not
so exempt, in compliance with the requirements of Section 409A. If the Board determines that any Award granted hereunder is not exempt
from and is therefore subject to Section 409A, the Award Agreement evidencing such Award will incorporate the terms and conditions
necessary to avoid the consequences specified in Section 409A(a)(1) of the Code, and to the extent an Award Agreement is silent
on terms necessary for compliance, such terms are hereby incorporated by reference into the Award Agreement. Notwithstanding anything
to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of the Common Stock are publicly
traded, and if a Participant holding an Award that constitutes “deferred compensation” under Section 409A is a “specified
employee” for purposes of Section 409A, no distribution or payment of any amount that is due because of a “separation
from service” (as defined in Section 409A without regard to alternative definitions thereunder) will be issued or paid before
the date that is six months and one day following the date of such Participant’s “separation from service” or, if earlier,
the date of the Participant’s death, unless such distribution or payment can be made in a manner that complies with Section 409A,
and any amounts so deferred will be paid in a lump sum on the day after such six month period elapses, with the balance paid thereafter
on the original schedule.

 

     

     

    

 

(o)           Choice
of Law. This Plan and any controversy arising out of or relating to this Plan shall be governed by, and construed in accordance
with, the internal laws of the State of Delaware, without regard to conflict of law principles that would result in any application of
any law other than the law of the State of Delaware.

 

10.         COVENANTS
OF THE COMPANY.

 

The Company will seek to obtain
from each regulatory commission or agency, as may be deemed to be necessary, having jurisdiction over the Plan such authority as may be
required to grant Awards and to issue and sell shares of the Common Stock upon exercise or vesting of the Awards; provided, however, that
this undertaking will not require the Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable
pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory
commission or agency the authority that counsel for the Company deems necessary or advisable for the lawful issuance and sale of the Common
Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell the Common Stock upon exercise or
vesting of such Awards unless and until such authority is obtained. A Participant is not eligible for the grant of an Award or the subsequent
issuance of the Common Stock pursuant to the Award if such grant or issuance would be in violation of any Applicable Law.

 

11.          ADDITIONAL
RULES FOR AWARDS SUBJECT TO SECTION 409A.

 

(a)            Application.
Unless the provisions of this Section 11 of the Plan are expressly superseded by the provisions in the form of
Award Agreement, the provisions of this Section 11 shall apply and shall supersede anything to the contrary set forth in the
Award Agreement for a Non-Exempt Award.

 

(b)            Non-Exempt
Awards Subject to Non-Exempt Severance Arrangements. To the extent a Non-Exempt Award is subject to Section 409A due to
application of a Non-Exempt Severance Arrangement, the following provisions of this subsection (b) apply.

 

(i)               If
the Non-Exempt Award vests in the ordinary course during the Participant’s Continuous Service in accordance with the vesting schedule
set forth in the Award Agreement, and does not accelerate vesting under the terms of a Non-Exempt Severance Arrangement, in no event will
the shares be issued in respect of such Non-Exempt Award any later than the later of: (i) December 31st
of the calendar year that includes the applicable vesting date, or (ii) the 60th day that follows
the applicable vesting date.

 

     

     

    

 

(ii)              If
vesting of the Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with the Participant’s
Separation from Service, and such vesting acceleration provisions were in effect as of the date of grant of the Non-Exempt Award and,
therefore, are part of the terms of such Non-Exempt Award as of the date of grant, then the shares will be earlier issued in settlement
of such Non-Exempt Award upon the Participant’s Separation from Service in accordance with the terms of the Non-Exempt Severance
Arrangement, but in no event later than the 60th day that follows the date of the Participant’s
Separation from Service. However, if at the time the shares would otherwise be issued the Participant is subject to the distribution limitations
contained in Section 409A applicable to “specified employees,” as defined in Section 409A(a)(2)(B)(i) of the
Code, such shares shall not be issued before the date that is six months following the date of such Participant’s Separation from
Service, or, if earlier, the date of the Participant’s death that occurs within such six month period.

 

(iii)            If
vesting of a Non-Exempt Award accelerates under the terms of a Non-Exempt Severance Arrangement in connection with a Participant’s
Separation from Service, and such vesting acceleration provisions were not in effect as of the date of grant of the Non-Exempt Award and,
therefore, are not a part of the terms of such Non-Exempt Award on the date of grant, then such acceleration of vesting of the Non-Exempt
Award shall not accelerate the issuance date of the shares, but the shares shall instead be issued on the same schedule as set forth in
the Grant Notice as if they had vested in the ordinary course during the Participant’s Continuous Service, notwithstanding the vesting
acceleration of the Non-Exempt Award. Such issuance schedule is intended to satisfy the requirements of payment on a specified date or
pursuant to a fixed schedule, as provided under Treasury Regulations Section 1.409A-3(a)(4).

 

(c)            Treatment
of Non-Exempt Awards Upon a Corporate Transaction for Employees and Consultants. The provisions of this subsection (c) shall
apply and shall supersede anything to the contrary set forth in the Plan with respect to the permitted treatment of any Non-Exempt Award
in connection with a Corporate Transaction if the Participant was either an Employee or Consultant upon the applicable date of grant of
the Non-Exempt Award.

 

(i)            Vested
Non-Exempt Awards. The following provisions shall apply to any Vested Non-Exempt Award in connection with a Corporate Transaction:

 

(1)            If
the Corporate Transaction is also a Section 409A Change in Control then the Acquiring Entity may not assume, continue or substitute
the Vested Non-Exempt Award. Upon the Section 409A Change in Control the settlement of the Vested Non-Exempt Award will automatically
be accelerated and the shares will be immediately issued in respect of the Vested Non-Exempt Award. Alternatively, the Company may instead
provide that the Participant will receive a cash settlement equal to the Fair Market Value of the shares that would otherwise be issued
to the Participant upon the Section 409A Change in Control.

 

(2)            If
the Corporate Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or
substitute each Vested Non-Exempt Award. The shares to be issued in respect of the Vested Non-Exempt Award shall be issued to the Participant
by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if the Corporate Transaction had
not occurred. In the Acquiring Entity’s discretion, in lieu of an issuance of shares, the Acquiring Entity may instead substitute
a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would otherwise be issued to the Participant
on such issuance dates, with the determination of the Fair Market Value of the shares made on the date of the Corporate Transaction.

 

     

     

    

 

(ii)           Unvested
Non-Exempt Awards. The following provisions shall apply to any Unvested Non-Exempt Award unless otherwise determined by the
Board pursuant to Section 11(e).

 

(1)            In
the event of a Corporate Transaction, the Acquiring Entity shall assume, continue or substitute any Unvested Non-Exempt Award. Unless
otherwise determined by the Board, any Unvested Non-Exempt Award will remain subject to the same vesting and forfeiture restrictions that
were applicable to the Award prior to the Corporate Transaction. The shares to be issued in respect of any Unvested Non-Exempt Award shall
be issued to the Participant by the Acquiring Entity on the same schedule that the shares would have been issued to the Participant if
the Corporate Transaction had not occurred. In the Acquiring Entity’s discretion, in lieu of an issuance of shares, the Acquiring
Entity may instead substitute a cash payment on each applicable issuance date, equal to the Fair Market Value of the shares that would
otherwise be issued to the Participant on such issuance dates, with the determination of Fair Market Value of the shares made on the date
of the Corporate Transaction.

 

(2)            If
the Acquiring Entity will not assume, substitute or continue any Unvested Non-Exempt Award in connection with a Corporate Transaction,
then such Award shall automatically terminate and be forfeited upon the Corporate Transaction with no consideration payable to any Participant
in respect of such forfeited Unvested Non-Exempt Award. Notwithstanding the foregoing, to the extent permitted and in compliance with
the requirements of Section 409A, the Board may in its discretion determine to elect to accelerate the vesting and settlement of
the Unvested Non-Exempt Award upon the Corporate Transaction, or instead substitute a cash payment equal to the Fair Market Value of such
shares that would otherwise be issued to the Participant, as further provided in subsection (e)(ii) below. In the absence of such
discretionary election by the Board, any Unvested Non-Exempt Award shall be forfeited without payment of any consideration to the affected
Participants if the Acquiring Entity will not assume, substitute or continue the Unvested Non-Exempt Awards in connection with the Corporate
Transaction.

 

(3)            The
foregoing treatment shall apply with respect to all Unvested Non-Exempt Awards upon any Corporate Transaction, and regardless of whether
or not such Corporate Transaction is also a Section 409A Change in Control.

 

(d)           Treatment
of Non-Exempt Awards Upon a Corporate Transaction for Non-Employee Directors. The following provisions of this subsection (d) shall
apply and shall supersede anything to the contrary that may be set forth in the Plan with respect to the permitted treatment of a Non-Exempt
Director Award in connection with a Corporate Transaction.

 

(i)            If
the Corporate Transaction is also a Section 409A Change in Control then the Acquiring Entity may not assume, continue or substitute
the Non-Exempt Director Award. Upon the Section 409A Change in Control the vesting and settlement of any Non-Exempt Director Award
will automatically be accelerated and the shares will be immediately issued to the Participant in respect of the Non-Exempt Director Award.
Alternatively, the Company may provide that the Participant will instead receive a cash settlement equal to the Fair Market Value of the
shares that would otherwise be issued to the Participant upon the Section 409A Change in Control pursuant to the preceding provision.

 

(ii)            If
the Corporate Transaction is not also a Section 409A Change in Control, then the Acquiring Entity must either assume, continue or
substitute the Non-Exempt Director Award. Unless otherwise determined by the Board, the Non-Exempt Director Award will remain subject
to the same vesting and forfeiture restrictions that were applicable to the Award prior to the Corporate Transaction. The shares to be
issued in respect of the Non-Exempt Director Award shall be issued to the Participant by the Acquiring Entity on the same schedule that
the shares would have been issued to the Participant if the Corporate Transaction had not occurred. In the Acquiring Entity’s discretion,
in lieu of an issuance of shares, the Acquiring Entity may instead substitute a cash payment on each applicable issuance date, equal to
the Fair Market Value of the shares that would otherwise be issued to the Participant on such issuance dates, with the determination of
Fair Market Value made on the date of the Corporate Transaction.

 

     

     

    

 

(e)           If
the RSU Award is a Non-Exempt Award, then the provisions in this Section 11(e) shall apply and supersede anything to the
contrary that may be set forth in the Plan or the Award Agreement with respect to the permitted treatment of such Non-Exempt Award:

 

(i)            Any
exercise by the Board of discretion to accelerate the vesting of a Non-Exempt Award shall not result in any acceleration of the scheduled
issuance dates for the shares in respect of the Non-Exempt Award unless earlier issuance of the shares upon the applicable vesting dates
would be in compliance with the requirements of Section 409A.

 

(ii)            The
Company explicitly reserves the right to earlier settle any Non-Exempt Award to the extent permitted and in compliance with the requirements
of Section 409A, including pursuant to any of the exemptions available in Treasury Regulations Section 1.409A-3(j)(4)(ix).

 

(iii)            To
the extent the terms of any Non-Exempt Award provide that it will be settled upon a Change in Control or Corporate Transaction, to the
extent it is required for compliance with the requirements of Section 409A, the Change in Control or Corporate Transaction event
triggering settlement must also constitute a Section 409A Change in Control. To the extent the terms of a Non-Exempt Award provides
that it will be settled upon a termination of employment or termination of Continuous Service, to the extent it is required for compliance
with the requirements of Section 409A, the termination event triggering settlement must also constitute a Separation From Service.
However, if at the time the shares would otherwise be issued to a Participant in connection with a “separation from service”
such Participant is subject to the distribution limitations contained in Section 409A applicable to “specified employees,”
as defined in Section 409A(a)(2)(B)(i) of the Code, such shares shall not be issued before the date that is six months following
the date of the Participant’s Separation From Service, or, if earlier, the date of the Participant’s death that occurs within
such six month period.

 

(iv)            The
provisions in this subsection (e) for delivery of the shares in respect of the settlement of an RSU Award that is a Non-Exempt Award
are intended to comply with the requirements of Section 409A so that the delivery of the shares to the Participant in respect of
such Non-Exempt Award will not trigger the additional tax imposed under Section 409A, and any ambiguities herein will be so interpreted.

 

12.          SEVERABILITY.

 

If all or any part of the
Plan or any Award Agreement is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity
shall not invalidate any portion of the Plan or such Award Agreement not declared to be unlawful or invalid. Any Section of the Plan
or any Award Agreement (or part of such a Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner
which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful
and valid.

 

13.          TERMINATION
OF THE PLAN.

 

The Board may suspend or terminate
the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier of: (i) the Adoption Date,
or (ii) the date the Plan is approved by the Company’s stockholders. No Awards may be granted under the Plan while the Plan
is suspended or after it is terminated.

 

     

     

    

 

14.          DEFINITIONS.

 

As used in the Plan, the following
definitions apply to the capitalized terms indicated below:

 

(a)            “Acquiring
Entity” means the surviving or acquiring corporation (or its parent company) in connection with a Corporate Transaction.

 

(b)            “Adoption
Date” means the date the Plan is first approved by the Board or Compensation Committee.

 

(c)            “Affiliate”
means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in
Rule 405 promulgated under the Securities Act. The Board may determine the time or times at which “parent” or “subsidiary”
status is determined within the foregoing definition.

 

(d)            “Applicable
Law” means any applicable securities, federal, state, foreign, material local or municipal or other law, statute, constitution,
principle of common law, resolution, ordinance, code, edict, decree, rule, listing rule, regulation, judicial decision, ruling or requirement
issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Body (including
under the authority of any applicable self-regulating organization such as the Nasdaq Stock Market, New York Stock Exchange, or the Financial
Industry Regulatory Authority).

 

(e)            “Award”
means any right to receive the Common Stock, cash or other property granted under the Plan (including an Incentive Stock Option, a Nonstatutory
Stock Option, a Restricted Stock Award, an RSU Award, a SAR, a Performance Award or any Other Award).

 

(f)            “Award
Agreement” means a written or electronic agreement between the Company and a Participant evidencing the terms and conditions
of an Award. The Award Agreement generally consists of the Grant Notice and the agreement containing the written summary of the general
terms and conditions applicable to the Award and which is provided, including through electronic means, to a Participant along with the
Grant Notice.

 

(g)            “Board”
means the Board of Directors of the Company (or its designee). Any decision or determination made by the Board shall be a decision or
determination that is made in the sole discretion of the Board (or its designee), and such decision or determination shall be final and
binding on all Participants.

 

(h)            “Capitalization
Adjustment” means any change that is made in, or other events that occur with respect to, the Common Stock subject to the
Plan or subject to any Award after the Effective Date without the receipt of consideration by the Company through merger, consolidation,
reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring cash dividend,
stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any
similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards Board Accounting Standards
Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the
Company will not be treated as a Capitalization Adjustment.

 

     

     

    

 

(i)            “Cause”
has the meaning ascribed to such term in any written agreement between a Participant and the Company defining such term and, in the absence
of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events: (i) the Participant’s
dishonest statements or acts with respect to the Company or any Affiliate of the Company, or any current or prospective customers, suppliers,
vendors or other third parties with which such entity does business; (ii) the Participant’s commission of (A) a felony
or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) the Participant’s failure to perform
the Participant’s assigned duties and responsibilities to the reasonable satisfaction of the Company which failure continues, in
the reasonable judgment of the Company, after written notice given to the Participant by the Company; (iv) the Participant’s
gross negligence, willful misconduct or insubordination with respect to the Company or any Affiliate of the Company; or (v) the Participant’s
material violation of any provision of any agreement(s) between the Participant and the Company relating to noncompetition, nonsolicitation,
nondisclosure and/or assignment of inventions. The determination that a termination of the Participant’s Continuous Service is either
for Cause or without Cause will be made by the Board with respect to Participants who are executive officers of the Company and by the
Company’s Chief Executive Officer with respect to Participants who are not executive officers of the Company. Any determination
by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards
held by such Participant will have no effect upon any determination of the rights or obligations of the Company or such Participant for
any other purpose.

 

(j)            “Change
in Control” or “Change of Control” means the occurrence, in a single transaction or in a series
of related transactions, of any one or more of the following events; provided, however, to the extent necessary to avoid adverse personal
income tax consequences to the Participant in connection with an Award, also constitutes a Section 409A Change in Control:

 

(i)            any
Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined
voting power of the Company’s then outstanding securities other than by virtue of a merger, consolidation or similar transaction.
Notwithstanding the foregoing, a Change in Control shall not be deemed to occur (A) on account of the acquisition of securities of
the Company directly from the Company, (B) on account of the acquisition of securities of the Company by an investor, any affiliate
thereof or any other Exchange Act Person that acquires the Company’s securities in a transaction or series of related transactions
the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, or (C) solely because
the level of Ownership held by any Exchange Act Person (the “Subject Person”) exceeds the designated percentage
threshold of the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing
the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this sentence) as a result
of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any
additional voting securities that, assuming the repurchase or other acquisition had not occurred, increases the percentage of the then
outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control shall be
deemed to occur;

 

(ii)            there
is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after the
consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own,
directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding voting power
of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined outstanding voting
power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case in substantially the same
proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction;

 

     

     

    

 

(iii)            there
is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company
and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of
the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of which are Owned
by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company
immediately prior to such sale, lease, license or other disposition; or

 

(iv)             individuals
who, on the date the Plan is adopted by the Board, are members of the Board (the “Incumbent Board”) cease for
any reason to constitute at least a majority of the members of the Board; provided, however, that if the appointment or election (or nomination
for election) of any new Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still
in office, such new member shall, for purposes of this Plan, be considered as a member of the Incumbent Board.

 

Notwithstanding the foregoing
or any other provision of this Plan, (A) the term Change in Control shall not include a sale of assets, merger or other transaction
effected exclusively for the purpose of changing the domicile of the Company, and (B) the definition of Change in Control (or any
analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing
definition with respect to Awards subject to such agreement; provided, however, that if no definition of Change in Control or any analogous
term is set forth in such an individual written agreement, the foregoing definition shall apply.

 

(k)            “Code”
means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.

 

(l)             “Committee”
means the Compensation Committee and any other committee of one or more Directors to whom authority has been delegated by the Board or
Compensation Committee in accordance with the Plan.

 

(m)           “Common
Stock” means the Class A Common Stock of the Company.

 

(n)            “Company”
means NeuroBo Pharmaceuticals, Inc., a Delaware corporation.

 

(o)            “Compensation
Committee” means the Compensation Committee of the Board.

 

(p)            “Consultant”
means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services
and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated for
such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be considered
a “Consultant” for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant under this Plan
only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or the sale of the Company’s
securities to such person.

 

     

     

    

 

(q)            “Continuous
Service” means that the Participant’s service with the Company or an Affiliate, whether as an Employee, Director or
Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate
as an Employee, Director or Consultant or a change in the Entity for which the Participant renders such service, provided that there is
no interruption or termination of the Participant’s service with the Company or an Affiliate, will not terminate a Participant’s
Continuous Service; provided, however, that if the Entity for which a Participant is rendering services ceases to qualify as an
Affiliate, as determined by the Board, such Participant’s Continuous Service will be considered to have terminated on the date such
Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Consultant of an Affiliate
or to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the Chief Executive
Officer of the Company, in that party’s sole discretion, may determine whether Continuous Service will be considered interrupted
in the case of (i) any leave of absence approved by the Board or chief executive officer, including sick leave, military leave or
any other personal leave, or (ii) transfers between the Company, an Affiliate, or their successors. Notwithstanding the foregoing,
a leave of absence will be treated as Continuous Service for purposes of vesting in an Award only to such extent as may be provided in
the Company’s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant,
or as otherwise required by law. In addition, to the extent required for exemption from or compliance with Section 409A, the determination
of whether there has been a termination of Continuous Service will be made, and such term will be construed, in a manner that is consistent
with the definition of “separation from service” as defined under Treasury Regulation Section 1.409A-1(h) (without
regard to any alternative definition thereunder).

 

(r)            “Corporate
Transaction” means the consummation, in a single transaction or in a series of related transactions, of any one or more
of the following events:

 

(i)            a
sale or other disposition of all or substantially all, as determined by the Board, of the consolidated assets of the Company and its Subsidiaries;

 

(ii)            a
sale or other disposition of at least 50% of the outstanding securities of the Company;

 

(iii)            a
merger, consolidation or similar transaction following which the Company is not the surviving corporation; or

 

(iv)            a
merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of the Common Stock
outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger,
consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.

 

Notwithstanding the foregoing
or any other provision of this Plan, (A) the term Corporate Transaction shall not include a sale of assets, merger or other transaction
effected exclusively for the purpose of changing the domicile of the Company, (B) the definition of Corporate Transaction (or any
analogous term) in an individual written agreement between the Company or any Affiliate and the Participant shall supersede the foregoing
definition with respect to Awards subject to such agreement; provided, however, that if no definition of Corporate Transaction or any
analogous term is set forth in such an individual written agreement, the foregoing definition shall apply, and (C) with respect to
any nonqualified deferred compensation that becomes payable on account of the Corporate Transaction, the transaction or event described
in clause (i), (ii), (iii), or (iv) also constitutes a Section 409A Change in Control if required in order for the payment not
to violate Section 409A of the Code.

 

(s)            “Director”
means a member of the Board.

 

(t)            “determine”
or “determined” means as determined by the Board or the Committee (or its designee) in its sole discretion.

 

     

     

    

 

(u)            “Disability”
means, with respect to a Participant, such Participant is unable to engage in any substantial gainful activity by reason of any medically
determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for
a continuous period of not less than 12 months, as provided in Section 22(e)(3) of the Code, and will be determined by the Board
on the basis of such medical evidence as the Board deems warranted under the circumstances.

 

(v)            “Effective
Date” means the effective date of this Plan, which is the date this Plan (as amended from time to time) is approved by the
Company’s stockholders.

 

(w)            “Employee”
means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services,
will not cause a Director to be considered an “Employee” for purposes of the Plan.

 

(x)            “Employer”
means the Company or the Affiliate of the Company that employs the Participant.

 

(y)            “Entity”
means a corporation, partnership, limited liability company or other entity.

 

(z)            “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

(aa)         “Exchange
Act Person” means any natural person, Entity or “group” (within the meaning of Section 13(d) or 14(d) of
the Exchange Act), except that “Exchange Act Person” will not include (i) the Company or any Subsidiary of the Company,
(ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities
under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities
pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the stockholders of
the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity or
 “group” (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date,
is the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company’s
then outstanding securities.

 

(bb)         “Fair
Market Value” means, as of any date, unless otherwise determined by the Board, the value of the Common Stock (as determined
on a per share or aggregate basis, as applicable) determined as follows:

 

(i)               If
the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value will be the closing
sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the
Common Stock) on the date of determination, as reported in a source the Board deems reliable.

 

(ii)              If
there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the closing selling
price on the last preceding date for which such quotation exists.

 

(iii)            In
the absence of such markets for the Common Stock, or if otherwise determined by the Board, the Fair Market Value will be determined by
the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code.

 

     

     

    

  

(cc)         “Fully
Diluted Shares” as of a date means an amount equal to the number of shares of Common Stock (i) outstanding and (ii) issuable
upon exercise, conversion or settlement of outstanding Awards under the Plan and any other outstanding options, warrants or other securities
of the Company that are (directly or indirectly) convertible or exchangeable into or exercisable for shares of Common Stock, in each case
as of the close of business of the Company on such date and without regard to any vesting conditions or other limitations on the immediate
ability to convert, exchange or exercise such rights. For purposes of calculating the number of Fully Diluted Shares, if the number of
shares subject to an outstanding right to acquire shares is variable, then the number of shares of Common Stock issuable upon exercise,
conversion, exchange or settlement of the right shall be the maximum number of shares that could be received under such right.

 

(dd)         “Governmental
Body” means any: (i) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction
of any nature; (ii) federal, state, local, municipal, foreign or other government; (iii) governmental or regulatory body, or
quasi-governmental body of any nature (including any governmental division, department, administrative agency or bureau, commission, authority,
instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity and any court or other tribunal, and
for the avoidance of doubt, any Tax authority) or other body exercising similar powers or authority; or (iv) self-regulatory
organization (including the Nasdaq Stock Market, New York Stock Exchange, and the Financial Industry Regulatory Authority).

 

(ee)         “Grant
Notice” means the notice provided to a Participant that he or she has been granted an Award under the Plan and which includes
the name of the Participant, the type of Award, the date of grant of the Award, number of shares of the Common Stock subject to the Award
or potential cash payment right, (if any), the vesting schedule for the Award (if any) and other key terms applicable to the Award.

 

(ff)          “Incentive
Stock Option” means an option granted pursuant to Section 4 of the Plan that is intended to be, and qualifies
as, an “incentive stock option” within the meaning of Section 422 of the Code.

 

(gg)        “Materially
Impair” means any amendment to the terms of the Award that materially adversely affects the Participant’s rights under
the Award. A Participant’s rights under an Award will not be deemed to have been Materially Impaired by any such amendment if the
Board, in its sole discretion, determines that the amendment, taken as a whole, does not Materially Impair the Participant’s rights.
For example, the following types of amendments to the terms of an Award do not Materially Impair the Participant’s rights under
the Award: (i) imposition of reasonable restrictions on the minimum number of shares subject to an Option or SAR that may be exercised;
(ii) to maintain the qualified status of the Award as an Incentive Stock Option under Section 422 of the Code; (iii) to
change the terms of an Incentive Stock Option in a manner that disqualifies, impairs or otherwise affects the qualified status of the
Award as an Incentive Stock Option under Section 422 of the Code; (iv) to clarify the manner of exemption from, or to bring
the Award into compliance with or qualify it for an exemption from, Section 409A; or (v) to comply with other Applicable Laws.

 

(hh)        “Non-Employee
Director” means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does
not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in
any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation
S-K promulgated pursuant to the Securities Act (“Regulation S-K”)), does not possess an interest in any other
transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged in a business relationship
for which disclosure would be required pursuant to Item 404(b) of Regulation S-K; or (ii) is otherwise considered a “non-employee
director” for purposes of Rule 16b-3.

 

     

     

    

 

(ii)            “Non-Exempt
Award” means any Award that is subject to, and not exempt from, Section 409A, including as the result of (i) a
deferral of the issuance of the shares subject to the Award which is elected by the Participant or imposed by the Company, or (ii) the
terms of any Non-Exempt Severance Agreement.

 

(jj)          “Non-Exempt
Director Award” means a Non-Exempt Award granted to a Participant who was a Director but not an Employee on the applicable
grant date.

 

(kk)        “Non-Exempt
Severance Arrangement” means a severance arrangement or other agreement between the Participant and the Company that provides
for acceleration of vesting of an Award and issuance of the shares in respect of such Award upon the Participant’s termination of
employment or separation from service (as such term is defined in Section 409A(a)(2)(A)(i) of the Code (and without regard to
any alternative definition thereunder) (“Separation from Service”) and such severance benefit does not satisfy
the requirements for an exemption from application of Section 409A provided under Treasury Regulations Section 1.409A-1(b)(4),
1.409A-1(b)(9) or otherwise.

 

(ll)          “Nonstatutory
Stock Option” means any option granted pursuant to Section 4 of the Plan that does not qualify as an Incentive
Stock Option.

 

(mm)      “Officer”
means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.

 

(nn)        “Option”
means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of the Common Stock granted pursuant to the Plan.

 

(oo)          “Option
Agreement” means a written or electronic agreement between the Company and the Optionholder evidencing the terms and conditions
of the Option grant. The Option Agreement includes the Grant Notice for the Option and the agreement containing the written summary of
the general terms and conditions applicable to the Option and which is provided, including through electronic means, to a Participant
along with the Grant Notice. Each Option Agreement will be subject to the terms and conditions of the Plan.

 

(pp)         “Optionholder”
means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Option.

 

(qq)         “Other
Award” means an award valued in whole or in part by reference to, or otherwise based on, Common Stock, including the appreciation
in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100% of the Fair Market Value at the
time of grant) that is not an Incentive Stock Option, Nonstatutory Stock Option, SAR, Restricted Stock Award, RSU Award or Performance
Award.

 

(rr)         “Other
Award Agreement” means a written agreement between the Company and a holder of an Other Award evidencing the terms and conditions
of an Other Award grant. Each Other Award Agreement will be subject to the terms and conditions of the Plan.

 

(ss)         “Own”,
“Owned”, “Owner” or “Ownership” means that a person or Entity
will be deemed to “Own,” to have “Owned,” to be the “Owner” of, or to have acquired “Ownership”
of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise,
has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.

 

     

     

    

 

(tt)          “Participant”
means an Employee, Director or Consultant to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds
an outstanding Award.

 

(uu)        “Performance
Award” means an Award that may vest or may be exercised or a cash award that may vest or become earned and paid contingent
upon the attainment during a Performance Period of certain Performance Goals and which is granted under the terms and conditions of Section 5(b) pursuant
to such terms as are approved by the Board. In addition, to the extent permitted by Applicable Law and set forth in the applicable Award
Agreement, the Board may determine that cash or other property may be used in payment of Performance Awards. Performance Awards that are
settled in cash or other property are not required to be valued in whole or in part by reference to, or otherwise based on, the Common
Stock.

 

(vv)          “Performance
Criteria” means one or more criteria that the Board will select for purposes of establishing the Performance Goals for a
Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on any one of, or combination
of, the following as determined by the Board: earnings (including earnings per share and net earnings); earnings before interest, taxes
and depreciation; earnings before interest, taxes, depreciation and amortization; total stockholder return; return on equity or average
stockholder’s equity; return on assets, investment, or capital employed; stock price; margin (including gross margin); income (before
or after taxes); operating income; operating income after taxes; pre-tax profit; operating cash flow; sales or revenue targets; increases
in revenue or product revenue; expenses and cost reduction goals; improvement in or attainment of working capital levels; economic value
added (or an equivalent metric); market share; cash flow; cash flow per share; share price performance; debt reduction; customer satisfaction;
stockholders’ equity; capital expenditures; debt levels; operating profit or net operating profit; workforce diversity; growth of
net income or operating income; billings; product development goals; financing; regulatory milestones, including approval of a product;
stockholder liquidity; corporate governance and compliance; product commercialization; intellectual property; personnel matters; progress
of internal research; progress of partnered programs; partner satisfaction; budget management; data from clinical studies, partner or
collaborator achievements; internal controls, including those related to the Sarbanes-Oxley Act of 2002; investor relations, analysts
and communication; manufacturing achievements (including obtaining particular yields from manufacturing runs and other measurable objectives
relates to process development activities); employee retention; strategic partnerships or transactions (including in-licensing and out-licensing
of intellectual property); establishing relationships with commercial entities with respect to the marketing, distribution and sale of
the Company’s products; supply chain achievements; co-development, co-marketing, profit sharing, joint venture or other similar
arrangements; individual performance goals; corporate development and planning goals; and other measures of performance selected by the
Board or Committee whether or not listed herein.

 

(ww)        “Performance
Goals” means, for a Performance Period, one or more goals established by the Board for the Performance Period based upon
the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions,
Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the
performance of one or more relevant indices. Unless specified otherwise by the Board (i) in the Award Agreement at the time the Award
is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance Goals are established,
the Board will appropriately make adjustments in the method of calculating the attainment of Performance Goals for a Performance Period
as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange rate effects; (3) to
exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of any statutory adjustments
to corporate tax rates; (5) to exclude the effects of items that are “unusual” in nature or occur “infrequently”
as determined under generally accepted accounting principles; (6) to exclude the dilutive effects of acquisitions or joint ventures;
(7) to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of
a Performance Period following such divestiture; (8) to exclude the effect of any change in the outstanding shares of common stock
of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, spin-off,
combination or exchange of shares or other similar corporate change, or any distributions to common stockholders other than regular cash
dividends; (9) to exclude the effects of stock based compensation and the award of bonuses under the Company’s bonus plans;
(10) to exclude costs incurred in connection with potential acquisitions or divestitures that are required to be expensed under generally
accepted accounting principles; and (11) to exclude the goodwill and intangible asset impairment charges that are required to be
recorded under generally accepted accounting principles. In addition, the Board may establish or provide for other adjustment items in
the Award Agreement at the time the Award is granted or in such other document setting for the Performance Goals at the time the Performance
Goals are established. In addition, the Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon
attainment of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for such Performance
Period. Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement
as specified in the Award Agreement or the written terms of a Performance Cash Award.

 

     

     

    

 

(xx)          “Performance
Period” means the period of time selected by the Board over which the attainment of one or more Performance Goals will be
measured for the purpose of determining a Participant’s right to vesting or exercise of an Award. Performance Periods may be of
varying and overlapping duration, at the sole discretion of the Board.

 

(yy)         “Plan”
means this NeuroBo Pharmaceuticals, Inc. 2022 Equity Incentive Plan, as amended from time to time.

 

(zz)         “Plan
Administrator” means the person, persons, and/or third-party administrator designated by the Company to administer the day
to day operations of the Plan.

 

(aaa)       “Post-Termination
Exercise Period” means the period following termination of a Participant’s Continuous Service within which an Option
or SAR is exercisable, as specified in Section 4(h).

 

(bbb)       “Prior
Plan’s Available Reserve” means the number of shares available for the grant of new awards under the Prior
Plan as of the Effective Date.

 

(ccc)       “Prior
Plan” means the Gemphire Therapeutics, Inc. 2019 Equity Incentive Plan.

 

(ddd)       “Prospectus”
means the document containing the Plan information specified in Section 10(a) of the Securities Act.

 

(eee)       “Restricted
Stock Award” or “RSA” means an Award of shares of the Common Stock which is granted pursuant to
the terms and conditions of Section 5(a).

 

(fff)         “Restricted
Stock Award Agreement” means a written or electronic agreement between the Company and a holder of a Restricted Stock Award
evidencing the terms and conditions of a Restricted Stock Award grant. The Restricted Stock Award Agreement includes the Grant Notice
for the Restricted Stock Award and the agreement containing the written summary of the general terms and conditions applicable to the
Restricted Stock Award and which is provided, including by electronic means, to a Participant along with the Grant Notice. Each Restricted
Stock Award Agreement will be subject to the terms and conditions of the Plan.

 

     

     

    

 

(ggg)      “Returning
Shares” means shares subject to outstanding stock awards granted under the Prior Plan and that following the Effective Date: (A) are
not issued because such stock award or any portion thereof expires or otherwise terminates without all of the shares covered by such stock
award having been issued; (B) are not issued because such stock award or any portion thereof is settled in cash; (C) are
forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of
such shares; (D) are withheld or reacquired to satisfy the exercise, strike or purchase price; or (E) are withheld
or reacquired to satisfy a tax withholding obligation.

 

(hhh)      “RSU
Award” or “RSU” means an Award of restricted stock units representing the right to receive an
issuance of shares of the Common Stock which is granted pursuant to the terms and conditions of Section 5(a).

 

(iii)          “RSU
Award Agreement” means a written or electronic agreement between the Company and a holder of an RSU Award evidencing the
terms and conditions of an RSU Award grant. The RSU Award Agreement includes the Grant Notice for the RSU Award and the agreement containing
the written summary of the general terms and conditions applicable to the RSU Award and which is provided, including by electronic means,
to a Participant along with the Grant Notice. Each RSU Award Agreement will be subject to the terms and conditions of the Plan.

 

(jjj)         “Rule 16b-3”
means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time to time.

 

(kkk)     “Rule 405”
means Rule 405 promulgated under the Securities Act.

 

(lll)         “Section 409A”
means Section 409A of the Code and the regulations and other guidance thereunder.

 

(mmm)   “Section 409A
Change in Control” means a change in the ownership or effective control of the Company, or in the ownership of a substantial
portion of the Company’s assets, as provided in Section 409A(a)(2)(A)(v) of the Code and Treasury Regulations Section 1.409A-3(i)(5) (without
regard to any alternative definition thereunder).

 

(nnn)      “Securities
Act” means the Securities Act of 1933, as amended.

 

(ooo)        “Share
Reserve” means the number of shares available for issuance under the Plan as set forth in Section 2(a).

 

(ppp)       “Stock
Appreciation Right” or “SAR” means a right to receive the appreciation on the Common Stock that
is granted pursuant to the terms and conditions of Section 4.

 

(qqq)       “SAR
Agreement” means a written or electronic agreement between the Company and a holder of a SAR evidencing the terms and conditions
of a SAR grant. The SAR Agreement includes the Grant Notice for the SAR and the agreement containing the written summary of the general
terms and conditions applicable to the SAR and which is provided, including by electronic means, to a Participant along with the Grant
Notice. Each SAR Agreement will be subject to the terms and conditions of the Plan.

 

     

     

    

 

(rrr)       “Subsidiary”
means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary voting
power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class
or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the time, directly
or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity in which the Company has
a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution) of more than 50%.

 

(sss)       “Ten
Percent Stockholder” means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock
possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.

 

(ttt)         “Trading
Policy” means the Company’s policy permitting certain individuals to sell Company shares only during certain “window”
periods and/or otherwise restricts the ability of certain individuals to transfer or encumber Company shares, as in effect from time to
time.

 

(uuu)      “Unvested
Non-Exempt Award” means the portion of any Non-Exempt Award that had not vested in accordance with its terms upon or prior
to the date of any Corporate Transaction.

 

(vvv)        “Vested
Non-Exempt Award” means the portion of any Non-Exempt Award that had vested in accordance with its terms upon or prior to
the date of a Corporate Transaction.

 

* * * *Exhibit 10.2

 

Standard RSU Package

 

NEUROBO PHARMACEUTICALS, INC.

RSU AWARD GRANT NOTICE

(2022 EQUITY INCENTIVE PLAN)

 

NeuroBo
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has awarded to you (the “Participant”)
the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU
Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2022
Equity Incentive Plan (the “Plan”) and the Award Agreement (the “Agreement”), which
are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan
or the Agreement shall have the meanings set forth in the Plan or the Agreement.

 

	Participant:	 	 
	Date of
    Grant:	 	 
	Vesting
    Commencement Date:	 	 
	Number
    of Restricted Stock Units:	 	 

 

	Vesting Schedule:	[	 	]

 

	 	Notwithstanding the foregoing, vesting shall terminate upon the Participant’s termination of Continuous Service.

 

		Issuance
                           Schedule:	One share of Common Stock will be issued for each restricted
stock unit which vests at the time set forth in Section 5 of the Agreement.

 

Participant
Acknowledgements: By your signature below or by electronic acceptance or authentication in a form authorized by the Company,
you understand and agree that:

 

		•	The RSU Award is governed by this RSU Award Grant Notice (the “Grant Notice”),
and the provisions of the Plan and the Agreement, all of which are made a part of this document. Unless otherwise provided in the Plan,
this Grant Notice and the Agreement (together, the “RSU Award Agreement”) may not be modified, amended or revised
except in a writing signed by you and a duly authorized officer of the Company.

 

		•	You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the Prospectus.
In the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms
of the Plan shall control.

 

		•	To the fullest extent permitted under the Plan and applicable law, any withholding taxes applicable to
the RSU Award will be satisfied through the sale of a number of the shares issuable in settlement of the RSU Award as determined in accordance
with Section 4 of the Agreement and the remittance of the cash proceeds to the Company. Under the Agreement, the Company or,
if different, your employer shall make payment from the cash proceeds of this sale directly to the appropriate tax or social security
authorities in an amount equal to the taxes required to be remitted. The mandatory sale of shares to cover withholding taxes is
imposed by the Company on you in connection with your receipt of this RSU Award.

 

    	 	1	 

     

    

 

		•	The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the
acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with
the exception of: (i) other equity awards previously granted to you, (ii) any written employment agreement, offer letter, severance
agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies the terms
that should govern this RSU Award, and (iii) any clawback policy that the Company is required to adopt pursuant to the listing standards
of any national securities exchange or association on which the Company’s securities are listed or as is otherwise required by the
Dodd-Frank Wall Street Reform and Consumer Protection Act or other Applicable Law.

 

	
    THE COMPANY:

     

    NeuroBo
Pharmaceuticals, Inc.
	 	
    PARTICIPANT:

     

	 	 	 
	By:	 	 	 
	Name:	 	 	[Insert Name]
	Title:	 	 	 
	 	 	 	 
	Date:	                                 	 	Date:	                        

 

Attachments:
RSU Award Agreement, 2022 Equity Incentive Plan

 

    	 	2	 

     

    

 

NEUROBO PHARMACEUTICALS, INC.

2022 EQUITY INCENTIVE PLAN

AWARD AGREEMENT (RSU AWARD)

 

As reflected by your Restricted
Stock Unit Grant Notice (the “Grant Notice”), NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the
“Company”) has granted you a RSU Award under the Company’s 2022 Equity Incentive Plan (the “Plan”)
for the number of restricted stock units as indicated in your Grant Notice (the “RSU Award”). The terms of your
RSU Award as specified in this Award Agreement for your RSU Award (the “Agreement”) and the Grant Notice constitute
your “RSU Award Agreement”. Defined terms not explicitly defined in this Agreement but defined in the Grant
Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.

 

The general terms applicable
to your RSU Award are as follows:

 

1.             Governing
Plan Document. Your RSU Award is subject to all the provisions of the Plan, including but not limited to the provisions in:

 

(a)            Section 6
of the Plan regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your RSU Award;

 

(b)            Section 9(e) of
the Plan regarding the Company’s retained rights to terminate your Continuous Service notwithstanding the grant of the RSU Award;
and

 

(c)            Section 8
of the Plan regarding the tax consequences of your RSU Award.

 

Your RSU Award is further
subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant
to the Plan. In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall
control.

 

2.             Grant
of the RSU Award. This RSU Award represents your right to be issued on a future date the number of shares of the Company’s
Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice as modified to reflect any Capitalization
Adjustment and subject to your satisfaction of the vesting conditions set forth therein (the “Restricted Stock Units”).
Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the
Plan and the provisions of Section 3 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture
restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units covered
by your RSU Award.

 

3.             Dividends.
You shall receive no benefit or adjustment to your RSU Award with respect to any cash dividend, stock dividend or other distribution that
does not result from a Capitalization Adjustment as provided in the Plan; provided, however, that this sentence shall not apply with respect
to any shares of Common Stock that are delivered to you in connection with your RSU Award after such shares have been delivered to you.

 

    	 	1	 

     

    

 

4.             Withholding
Obligations.

 

(a)            You
acknowledge that, regardless of any action taken by the Company, or if different, the Affiliate employing or engaging you (the “Employer”),
the ultimate liability for all income tax (including U.S. federal, state, and local taxes and/or non-U.S. taxes), social insurance, payroll
tax, fringe benefits tax, payment on account or other tax-related items related to your participation in the Plan and legally applicable
to you (the “Tax-Related Items”) is and remains your responsibility and may exceed the amount, if any, actually
withheld by the Company or the Employer. You further acknowledge that the Company and/or the Employer (i) make no representations
or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSU Award, including, but not limited
to, the grant of the RSU Award, the vesting of the RSU Award, the issuance of shares in settlement of vesting of the RSU Award, the subsequent
sale of any shares of Common Stock acquired pursuant to the RSU Award and the receipt of any dividends or dividend equivalent; and (ii) do
not commit to and are under no obligation to reduce or eliminate your liability for Tax-Related Items. Further, if you become subject
to taxation in more than one country, you acknowledge that the Company and/or the Employer (or former employer, as applicable) may be
required to withhold or account for Tax-Related Items in more than one country.

 

(b)            On
each vesting date, and on or before the time you receive a distribution of the shares underlying your Restricted Stock Units, and at any
other time as reasonably requested by the Company in accordance with Applicable Law, you agree to make adequate provision for any sums
required to satisfy the withholding obligations of the Company, the Employer or any Affiliate in connection with any Tax-Related Items
that arise in connection with your RSU Award (the “Withholding Taxes”). The Company shall arrange a mandatory
sale (on your behalf pursuant to your authorization under this section and without further consent) of the shares of Common Stock issued
in settlement upon the vesting of your Restricted Stock Units in an amount necessary to satisfy the Withholding Taxes and shall satisfy
the Withholding Taxes by withholding from the proceeds of such sale (the “Mandatory Sell to Cover”). You hereby
acknowledge and agree that the Company shall have the authority to administer the Mandatory Sell to Cover arrangement in its sole discretion
with a registered broker-dealer that is a member of the Financial Industry Regulatory Authority (a “FINRA Dealer”)
as the Company may select as the agent (the “Agent”) who will sell on the open market at the then prevailing
market price(s), as soon as practicable on or after each date on which your Restricted Stock Units vest, the number (rounded up to the
next whole number) of the shares of Common Stock to be delivered to you in connection with the vesting of the Restricted Stock Units sufficient
to generate proceeds to cover (A) the Withholding Taxes that you are required to pay pursuant to the Plan and this Agreement as a
result of the vesting of the Restricted Stock Units (or shares being issued thereunder, as applicable) and (B) all applicable fees
and commissions due to, or required to be collected by, the Agent with respect thereto any remaining funds shall be remitted to you.

 

(c)            If,
for any reason, such Mandatory Sell to Cover does not result in sufficient proceeds to satisfy the Withholding Taxes, the Company or an
Affiliate may, in its sole discretion, satisfy all or any portion of the Withholding Taxes relating to your RSU Award by any of the following
means or by a combination of such means: (i) withholding from any compensation otherwise payable to you by the Company or the Employer;
(ii) causing you to tender a cash payment (which may be in the form of a check, electronic wire transfer or other method permitted
by the Company); or (iii) withholding shares of Common Stock from the shares of Common Stock issued or otherwise issuable to you
in connection with your Restricted Stock Units with a fair market value (measured as of the date shares of Common Stock are issued to
you) equal to the amount of such Withholding Taxes; provided, however, that the number of such shares of Common Stock so withheld will
not exceed the amount necessary to satisfy the Company’s required tax withholding obligations using the maximum statutory withholding
rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income;
and to the extent necessary to qualify for an exemption from application of Section 16(b) of the Exchange Act, if applicable,
such share withholding procedure will be subject to the express prior approval of the Company’s Board or Compensation Committee.

 

    	 	2	 

     

    

 

(d)            Unless
the tax withholding obligations of the Company and/or any Affiliate with respect to the Tax-Related Items are satisfied, the Company shall
have no obligation to deliver to you any Common Stock.

 

(e)            In
the event the Company’s obligation to withhold arises prior to the delivery to you of Common Stock or it is determined after the
delivery of Common Stock to you that the amount of the Tax-Related Items withholding obligation was greater than the amount withheld by
the Company or your Employer, you agree to indemnify and hold the Company and your Employer harmless from any failure by the Company or
your Employer to withhold the proper amount.

 

(f)            You
acknowledge that the Mandatory Sell to Cover is imposed by the Company on you pursuant to the terms of the RSU Award.

 

(g)            The
Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts, or other applicable
withholding rates, including maximum applicable rates in your jurisdiction(s). If the maximum rate is used, any over-withheld amount may
be refunded to you in cash by the Company or Employer (with no entitlement to the equivalent in shares of Common Stock), or if not refunded,
you may seek a refund from the local tax authorities. You must pay to the Company and/or the Employer any amount of Tax-Related Items
that the Company and/or the Employer may be required to withhold or account for as a result of your participation in the Plan that cannot
be satisfied by the means previously described.

 

5.             Date
of Issuance.

 

(a)            The
issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and
will be construed and administered in such a manner. Subject to the satisfaction of the Withholding Obligation, if any, in the event one
or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each Restricted Stock Unit
that vests on the applicable vesting date(s) (subject to any adjustment under Section 4 above, and subject to any different
provisions in the Grant Notice). Each issuance date determined by this paragraph is referred to as an “Original Issuance Date.”

 

(b)            Notwithstanding
the foregoing, if (i) selling shares of the Company’s Common Stock in the public market on the Original Issuance Date to satisfy
your tax withholding obligation in accordance with Section 4 of this Agreement is prohibited for any reason, and (ii) the
Company elects not to instead satisfy its tax withholding obligations by withholding shares from your distribution, then such shares shall
not be delivered on such Original Issuance Date and shall instead be delivered to you on the earliest of: (1) the first date that
you are not prohibited from selling shares of the Company’s Common Stock in the open market, or (2) such earlier date that
the Company elects to satisfy its tax withholding obligation by withholding shares from your distribution; provided, however, that notwithstanding
the foregoing, in no event will the shares be delivered to you any later than: (A) December 31 of the calendar year in which
the Original Issuance Date occurs (that is, the last day of the taxable year in which the Original Issuance Date occurs), or (B) if
and only if permitted in a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is
the 15th day of the third calendar month of the applicable year following the year in which the shares of Common Stock are no longer subject
to a “substantial risk of forfeiture” within the meaning of Treasury Regulations Section 1.409A-1(d). Delivery of the
shares is intended to comply with the requirements for the short-term deferral exemption available under Treasury Regulations Section 1.409A-1(b)(4) and
shall be construed and administered in such manner.

 

    	 	3	 

     

    

 

(c)            In
addition and notwithstanding the foregoing, no shares of Common Stock issuable to you under this Section 5 as a result of
the vesting of one or more Restricted Stock Units will be delivered to you until any filings that may be required pursuant to the Hart-Scott-Rodino
(“HSR”) Act in connection with the issuance of such shares have been filed and any required waiting period under
the HSR Act has expired or been terminated (any such filings and/or waiting period required pursuant to HSR, the “HSR Requirements”).
If the HSR Requirements apply to the issuance of any shares of Common Stock issuable to you under this Section 5 upon vesting
of one or more Restricted Stock Units, such shares of Common Stock will not be issued on the Original Issuance Date and will instead be
issued on the first business day on or following the date when all such HSR Requirements are satisfied and when you are permitted to sell
shares of Common Stock on an established stock exchange or stock market, as determined by the Company in accordance with the Company’s
then-effective policy on trading in Company securities. Notwithstanding the foregoing, the issuance date for any shares of Common Stock
delayed under this Section 5(c) shall in no event be later than December 31 of the calendar year in which the Original
Issuance Date occurs (that is, the last day of your taxable year in which the Original Issuance Date occurs), unless a later issuance
date is permitted without incurring adverse tax consequences under Section 409A of the Code or other Applicable Law.

 

(d)            To
the extent the RSU Award is a Non-Exempt RSU Award, the provisions of Section 11 of the Plan shall apply.

 

6.             Transferability.
Except as otherwise provided in the Plan, your RSU Award is not transferable, except by will or by the applicable laws of descent and
distribution

 

7.             Corporate
Transaction. Your RSU Award is subject to the terms of any agreement governing a Corporate Transaction involving the Company,
including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf
with respect to any escrow, indemnities and any contingent consideration.

 

8.             No
Liability for Taxes. As a condition to accepting the RSU Award, you hereby (a) agree to not make any claim against the
Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company
compensation and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors
regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so.

 

9.             Severability.
If any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness
or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of
this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will
give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.

 

10.           Other
Documents. You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated
under the Securities Act, which includes the Prospectus. In addition, you acknowledge receipt of the Company’s Trading Policy.

 

11.           Questions.
If you have questions regarding these or any other terms and conditions applicable to your RSU Award, including a summary
of the applicable federal income tax consequences please see the Prospectus.

 

* * * *

 

    	 	4	 

     

    

 

Non-Employee Director RSU Package

 

NEUROBO PHARMACEUTICALS, INC.

RSU AWARD GRANT NOTICE

(2022 EQUITY INCENTIVE PLAN)

 

NeuroBo
Pharmaceuticals, Inc., a Delaware corporation (the “Company”) has awarded to you (the “Participant”)
the number of restricted stock units specified and on the terms set forth below in consideration of your services (the “RSU
Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2022
Equity Incentive Plan (the “Plan”) and the Award Agreement (the “Agreement”), which
are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan
or the Agreement shall have the meanings set forth in the Plan or the Agreement.

 

	Participant:	 	 
	Date of Grant:	 	 
	Vesting Commencement Date:	 	 
	Number of Restricted Stock Units:	 	 

 

	Vesting Schedule:	[	 	].

 

	 	Notwithstanding the foregoing, vesting shall terminate upon the Participant’s termination of Continuous Service.

 

		Issuance
                           Schedule:	One share of Common Stock will be issued for each restricted
stock unit which vests at the time set forth in Section 5 of the Agreement.

 

Participant
Acknowledgements: By your signature below or by electronic acceptance or authentication in a form authorized by the Company,
you understand and agree that:

 

		•	The RSU Award is governed by this RSU Award Grant Notice (the “Grant Notice”),
and the provisions of the Plan and the Agreement, all of which are made a part of this document. Unless otherwise provided in the Plan,
this Grant Notice and the Agreement (together, the “RSU Award Agreement”) may not be modified, amended or revised
except in a writing signed by you and a duly authorized officer of the Company.

 

		•	You have read and are familiar with the provisions of the Plan, the RSU Award Agreement and the Prospectus.
In the event of any conflict between the provisions in the RSU Award Agreement, or the Prospectus and the terms of the Plan, the terms
of the Plan shall control.

 

		•	The RSU Award Agreement sets forth the entire understanding between you and the Company regarding the
acquisition of Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with
the exception of: (i) other equity awards previously granted to you, and (ii) any written employment agreement, offer letter,
severance agreement, written severance plan or policy, or other written agreement between the Company and you in each case that specifies
the terms that should govern this RSU Award.

 

    	 	1	 

     

    

 

	
    THE COMPANY:

     

    NeuroBo
Pharmaceuticals, Inc.
	 	
    PARTICIPANT:

     

	 	 	 
	By:	 	 	 
	Name:	 	 	[Insert Name]
	Title:	 	 	 
	 	 	 	 
	Date:	                                 	 	Date:	                        

 

Attachments:
RSU Award Agreement, 2022 Equity Incentive Plan

 

    	 	2	 

     

    

 

NEUROBO PHARMACEUTICALS, INC.

2022 EQUITY INCENTIVE PLAN

AWARD AGREEMENT (RSU AWARD)

 

As reflected by your Restricted
Stock Unit Grant Notice (the “Grant Notice”), NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the
“Company”) has granted you a RSU Award under the Company’s 2022 Equity Incentive Plan (the “Plan”)
for the number of restricted stock units as indicated in your Grant Notice (the “RSU Award”). The terms of your
RSU Award as specified in this Award Agreement for your RSU Award (the “Agreement”) and the Grant Notice constitute
your “RSU Award Agreement”. Defined terms not explicitly defined in this Agreement but defined in the Grant
Notice or the Plan shall have the same definitions as in the Grant Notice or Plan, as applicable.

 

The general terms applicable
to your RSU Award are as follows:

 

1.             Governing
Plan Document. Your RSU Award is subject to all the provisions of the Plan, including but not limited to the provisions in:

 

(a)            Section 6
of the Plan regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your RSU Award;

 

(b)            Section 9(e) of
the Plan regarding the Company’s retained rights to terminate your Continuous Service notwithstanding the grant of the RSU Award;
and

 

(c)            Section 8
of the Plan regarding the tax consequences of your RSU Award.

 

Your RSU Award is further
subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant
to the Plan. In the event of any conflict between the RSU Award Agreement and the provisions of the Plan, the provisions of the Plan shall
control.

 

2.             Grant
of the RSU Award. This RSU Award represents your right to be issued on a future date the number of shares of the Company’s
Common Stock that is equal to the number of restricted stock units indicated in the Grant Notice as modified to reflect any Capitalization
Adjustment and subject to your satisfaction of the vesting conditions set forth therein (the “Restricted Stock Units”).
Any additional Restricted Stock Units that become subject to the RSU Award pursuant to Capitalization Adjustments as set forth in the
Plan and the provisions of Section 3 below, if any, shall be subject, in a manner determined by the Board, to the same forfeiture
restrictions, restrictions on transferability, and time and manner of delivery as applicable to the other Restricted Stock Units covered
by your RSU Award.

 

3.             Dividends.
You shall receive no benefit or adjustment to your RSU Award with respect to any cash dividend, stock dividend or other distribution that
does not result from a Capitalization Adjustment as provided in the Plan; provided, however, that this sentence shall not apply with respect
to any shares of Common Stock that are delivered to you in connection with your RSU Award after such shares have been delivered to you.

 

4.            Withholding
Obligations. As further provided in Section 8 of the Plan, you hereby authorize withholding from payroll and any
other amounts payable to you, and otherwise agree to make adequate provision for, any sums required to satisfy the federal, state, local
and foreign tax withholding obligations, if any, which arise in connection with your RSU Award (the “Withholding Obligation”)
in accordance with the withholding procedures established by the Company. Unless the Withholding Obligation is satisfied, the Company
shall have no obligation to deliver to you any Common Stock in respect of the RSU Award. In the event the Withholding Obligation of the
Company arises prior to the delivery to you of Common Stock or it is determined after the delivery of Common Stock to you that the amount
of the Withholding Obligation was greater than the amount withheld by the Company, you agree to indemnify and hold the Company harmless
from any failure by the Company to withhold the proper amount.

 

    	 	1	 

     

    

 

5.             Date
Of Issuance.

 

(a)            The
issuance of shares in respect of the Restricted Stock Units is intended to comply with Treasury Regulations Section 1.409A-1(b)(4) and
will be construed and administered in such a manner. Subject to the satisfaction of the Withholding Obligation, if any, in the event one
or more Restricted Stock Units vests, the Company shall issue to you one (1) share of Common Stock for each Restricted Stock Unit
that vests on the applicable vesting date(s) (subject to any adjustment under Section 3 above, and subject to any different
provisions in the Grant Notice). Each issuance date determined by this paragraph is referred to as an “Original Issuance Date.”

 

(b)            If
the Original Issuance Date falls on a date that is not a business day, delivery shall instead occur on the next following business day.
In addition, if:

 

(i)            the
Original Issuance Date does not occur (1) during an “open window period” applicable to you, as determined by the Company
in accordance with the Company’s then-effective policy on trading in Company securities, or (2) on a date when you are otherwise
permitted to sell shares of Common Stock on an established stock exchange or stock market (including but not limited to under a previously
established written trading plan that meets the requirements of Rule 10b5-1 under the Exchange Act and was entered into in compliance
with the Company’s policies (a “10b5-1 Arrangement”)), and

 

(ii)            either
(1) a Withholding Obligation does not apply, or (2) the Company decides, prior to the Original Issuance Date, (A) not to
satisfy the Withholding Obligation by withholding shares of Common Stock from the shares otherwise due, on the Original Issuance Date,
to you under this Award, and (B) not to permit you to enter into a “same day sale” commitment with a broker-dealer (including
but not limited to a commitment under a 10b5-1 Arrangement) and (C) not to permit you to pay your Withholding Obligation in cash,
then the shares that would otherwise be issued to you on the Original Issuance Date will not be delivered on such Original Issuance
Date and will instead be delivered on the first business day when you are not prohibited from selling shares of the Company’s Common
Stock in the open public market, but in no event later than December 31 of the calendar year in which the Original Issuance Date
occurs (that is, the last day of your taxable year in which the Original Issuance Date occurs), or, if and only if permitted in
a manner that complies with Treasury Regulations Section 1.409A-1(b)(4), no later than the date that is the 15th day of the third
calendar month of the applicable year following the year in which the shares of Common Stock under this Award are no longer subject to
a “substantial risk of forfeiture” within the meaning of Treasury Regulations Section 1.409A-1(d).

 

(c)            To
the extent the RSU Award is a Non-Exempt RSU Award, the provisions of Section 11 of the Plan shall apply.

 

6.             Transferability.
Except as otherwise provided in the Plan, your RSU Award is not transferable, except by will or by the applicable laws of descent and
distribution

 

7.             Corporate
Transaction. Your RSU Award is subject to the terms of any agreement governing a Corporate Transaction involving the Company,
including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf
with respect to any escrow, indemnities and any contingent consideration.

 

    	 	2	 

     

    

 

8.             No
Liability for Taxes. As a condition to accepting the RSU Award, you hereby (a) agree to not make any claim against the
Company, or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the RSU Award or other Company
compensation and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors
regarding the tax consequences of the RSU Award and have either done so or knowingly and voluntarily declined to do so.

 

9.             Severability.
If any part of this Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness
or invalidity will not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid. Any Section of
this Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which will
give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid.

 

10.           Other
Documents. You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated
under the Securities Act, which includes the Prospectus. In addition, you acknowledge receipt of the Company’s Trading Policy.

 

11.           Questions.
If you have questions regarding these or any other terms and conditions applicable to your RSU Award, including a summary of
the applicable federal income tax consequences please see the Prospectus.

 

* * * *

 

    	 	3	 

     

    

 

Standard Stock Option Grant Package

 

NEUROBO PHARMACEUTICALS, INC.

STOCK OPTION GRANT NOTICE

(2022 EQUITY INCENTIVE PLAN)

 

NeuroBo
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its 2022 Equity Incentive
Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number
of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and
conditions as set forth in this Stock Option Grant Notice (the “Grant Notice”) and in the Plan, the Stock Option
Agreement and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not
explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock
Option Agreement, as applicable.

 

	Optionholder:	
	 	 
	Date
    of Grant:	
	 	 
	Vesting
    Commencement Date:	
	 	 
	Number of Shares of the Common Stock
        Subject to Option:
	
	 	 
	Exercise
    Price (Per Share):	
	 	 
	Total
    Exercise Price:	
	 	 
	Expiration
    Date:	

 

	
    Type of Grant:
	[Incentive Stock Option] OR [Nonstatutory Stock Option]
	 	 
	Exercise and Vesting Schedule:	Subject
    to the Optionholder’s Continuous Service through each applicable vesting date, the Option will vest as follows:1

 

Optionholder
Acknowledgements: By your signature below or by electronic acceptance or authentication in a form authorized by the Company,
you understand and agree that:

 

		•	The Option is governed by the Grant Notice, and the provisions of the Plan, the Stock Option Agreement
and the Notice of Exercise, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and
the Stock Option Agreement (together, the “Option Agreement”) may not be modified, amended or revised except
in a writing signed by you and a duly authorized officer of the Company.

 

		•	If the Option is designated an Incentive Stock Option, it (plus other outstanding Incentive Stock Options
granted to you) cannot be first exercisable for more than $100,000 in value (measured by exercise price) in any calendar year. Any excess
over $100,000 is a Nonstatutory Stock Option.

 

 

1 Note to Draft: To insert applicable
vesting schedule

 

    	 	1	 

     

    

 

		•	You consent to receive this Grant Notice, the Stock Option Agreement, the Plan and any other Plan-related
documents (including the Prospectus) by electronic delivery and to participate in the Plan through an on-line or electronic system established
and maintained by the Company or another third party designated by the Company.

 

		•	You have read and are familiar with the provisions of the Plan, the Grant Notice, the Stock Option Agreement,
the Notice of Exercise and the Prospectus. In the event of any conflict between the provisions in this Grant Notice, the Option Agreement,
the Notice of Exercise, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.

 

		•	The Option Agreement sets forth the entire understanding between you and the Company regarding the acquisition
of the Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception
of other equity awards previously granted to you and any written employment agreement, offer letter, severance agreement, written severance
plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this Option.

 

		•	Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission
method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

	
    THE COMPANY:

     

    NeuroBo
Pharmaceuticals, Inc.
	 	
    OPTIONHOLDER:

     

	 	 	 
	By:	 	 	 
	Name:	 	 	[Insert Name]
	Title:	 	 	 
	 	 	 	 
	Date:	                                 	 	Date:	                        

  

ATTACHMENTS:
Stock Option Agreement, 2022 Equity Incentive Plan, Notice of Exercise

 

    	 	2	 

     

    

 

ATTACHMENT I

 

STOCK OPTION AGREEMENT

 

    	 	 	 

     

    

 

NEUROBO PHARMACEUTICALS, INC.

2022 EQUITY INCENTIVE PLAN

 

STOCK OPTION AGREEMENT

 

As reflected by your Stock
Option Grant Notice (the “Grant Notice”), NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company”)
has granted you an option under its 2022 Equity Incentive Plan (the “Plan”) to purchase a number of shares of
the Common Stock at the exercise price indicated in your Grant Notice (the “Option”). Capitalized terms not
explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the meanings set forth in the Grant Notice
or Plan, as applicable. The terms of your Option as specified in the Grant Notice and this Stock Option Agreement constitute your Option
Agreement.

 

The general terms and conditions
applicable to your Option are as follows:

 

1.             Governing
Plan Document. Your Option is subject to all the provisions of the Plan, including but not limited to the provisions in:

 

(a)            Section 6
regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your Option;

 

(b)            Section 9(e) regarding
the Company’s retained rights to terminate your Continuous Service notwithstanding the grant of the Option; and

 

(c)            Section 8
regarding the tax consequences of your Option.

 

Your Option is further subject
to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the
Plan. In the event of any conflict between the Option Agreement and the provisions of the Plan, the provisions of the Plan shall control.

 

2.             Vesting.

 

(a)            The
provisions of this Section 2 shall not apply to your Option if you have entered into a written agreement with the Company
that contains terms related to a 280G Payment (as defined below).

 

(b)            Your
Option will vest as provided in your Grant Notice, subject to the provisions contained herein and the terms of the Plan. Vesting will
cease upon the termination of your Continuous Service. Notwithstanding the foregoing, if a Change in Control occurs and your Continuous
Service has not terminated as of immediately prior to such Change in Control, then the vesting and exercisability of your Option will
be accelerated in full upon such Change in Control.

 

(c)            If
any payment or benefit you would receive from the Company or otherwise in connection with a Change in Control or other similar transaction
(a “280G Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G
of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise
Tax”), then any such 280G Payment (a “Payment”) shall be equal to the Reduced Amount. The “Reduced
Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after
reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount
(i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment
taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax
basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a
reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of
the preceding sentence, the reduction shall occur in the manner (the “Reduction Method”) that results in the
greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced
will be reduced pro rata (the “Pro Rata Reduction Method”).

 

    	 	1	 

     

    

 

Notwithstanding the foregoing,
if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to
Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction
Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to
Section 409A of the Code as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible,
the greatest economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent
on future events (e.g., being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future
events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A
of the Code shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A
of the Code.

 

Unless you and the Company
agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day
prior to the effective date of the change of control transaction triggering the Payment shall perform the foregoing calculations. If the
accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change
of control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder.
The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company
shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations,
together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which
your right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other time as
requested by you or the Company.

 

If you receive a Payment for
which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 2(b) and the
Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return
to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 2(b))
so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined
pursuant to clause (y) in the first paragraph of this Section 2(b), you

 

3.             Exercise.

 

(a)            You
may generally exercise the vested portion of your Option for whole shares of the Common Stock at any time during its term by delivery
of payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator in accordance
with the exercise procedures established by the Plan Administrator, which may include an electronic submission. Please review Sections
4(i), 4(j) and 7(b)(v) of the Plan, which may restrict or prohibit your ability to exercise your Option during
certain periods.

 

    	 	2	 

     

    

 

(b)            To
the extent permitted by Applicable Law, you may pay your Option exercise price as follows:

 

(i)             cash,
check, bank draft or money order;

 

(ii)            subject
to Company and/or Committee consent at the time of exercise, pursuant to a “cashless exercise” program as further described
in Section 4(c)(ii) of the Plan if at the time of exercise the Common Stock is publicly traded;

 

(iii)          subject
to Company and/or Committee consent at the time of exercise, by delivery of previously owned shares of the Common Stock as further described
in Section 4(c)(iii) of the Plan; or

 

(iv)           subject
to Company and/or Committee consent at the time of exercise, if the Option is a Nonstatutory Stock Option, by a “net exercise”
arrangement as further described in Section 4(c)(iv) of the Plan.

 

(c)            By
accepting your Option, you agree that you will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase
of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of the Common
Stock or other securities of the Company held by you, for a period of one hundred eighty (180) days following the effective date
of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will
request to facilitate compliance with FINRA Rule 2241 or any successor or similar rules or regulation (the “Lock-Up
Period”); provided, however, that nothing contained in this section will prevent the exercise of a repurchase option,
if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably
requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto.
In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of the Common
Stock until the end of such period. You also agree that any transferee of any shares of the Common Stock (or other securities) of the
Company held by you will be bound by this Section 3(c). The underwriters of the Company’s stock are intended third party
beneficiaries of this Section 3(c) and will have the right, power and authority to enforce the provisions hereof as though
they were a party hereto.

 

4.             Term.
 You may not exercise your Option before the commencement of its term or after its term expires. The term of your Option commences
on the Date of Grant and expires upon the earliest of the following:

 

(a)            immediately
upon the termination of your Continuous Service for Cause;

 

(b)            three
months after the termination of your Continuous Service for any reason other than Cause, Disability or death;

 

(c)            12
months after the termination of your Continuous Service due to your Disability;

 

(d)            18
months after your death if you die during your Continuous Service;

 

(e)            immediately
upon a Corporate Transaction if the Board has determined that the Option will terminate in connection with a Corporate Transaction;

 

    	 	3	 

     

    

 

(f)            the
Expiration Date indicated in your Grant Notice; or

 

(g)            the
day before the 10th anniversary of the Date of Grant.

 

Notwithstanding the foregoing,
if you die during the period provided in Section 3(b) or 3(c) above, the term of your Option shall not expire
until the earlier of (i) 18 months after your death, (ii) upon any termination of the Option in connection with a Corporate
Transaction, (iii) the Expiration Date indicated in your Grant Notice, or (iv) the day before the tenth anniversary of the Date
of Grant. Additionally, the Post-Termination Exercise Period of your Option may be extended as provided in Section 4(i) of
the Plan.

 

To obtain the federal income
tax advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the date of grant of your Option
and ending on the day three months before the date of your Option’s exercise, you must be an employee of the Company or an Affiliate,
except in the event of your death or Disability. If the Company provides for the extended exercisability of your Option under certain
circumstances for your benefit, your Option will not necessarily be treated as an Incentive Stock Option if you exercise your Option more
than three months after the date your employment terminates.

 

5.             Withholding
Obligations. As further provided in Section 8 of the Plan: (a) you may not exercise your Option unless
the applicable tax withholding obligations are satisfied, and (b) at the time you exercise your Option, in whole or in part, or at
any time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and
otherwise agree to make adequate provision for (including by means of a “cashless exercise” pursuant to a program developed
under Regulation T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the
federal, state, local and foreign tax withholding obligations, if any, which arise in connection with the exercise of your Option in accordance
with the withholding procedures established by the Company. Accordingly, you may not be able to exercise your Option even though the Option
is vested, and the Company shall have no obligation to issue shares of the Common Stock subject to your Option, unless and until such
obligations are satisfied. In the event that the amount of the Company’s withholding obligation in connection with your Option was
greater than the amount actually withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the
Company to withhold the proper amount.

  

6.             Incentive
Stock Option Disposition Requirement. If your Option is an Incentive Stock Option, you must notify the Company in writing within
15 days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your Option that occurs within
two years after the date of your Option grant or within one year after such shares of the Common Stock are transferred upon exercise of
your Option.

 

7.             Transferability.
Except as otherwise provided in Section 4(e) of the Plan, your Option is not transferable, except by will or by the
applicable laws of descent and distribution, and is exercisable during your life only by you.

 

8.             Corporate
Transaction. Your Option is subject to the terms of any agreement governing a Corporate Transaction involving the Company,
including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf
with respect to any escrow, indemnities and any contingent consideration.

 

    	 	4	 

     

    

 

9.             No
Liability for Taxes. As a condition to accepting the Option, you hereby (a) agree to not make any claim against the Company,
or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the Option or other Company compensation
and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the
tax consequences of the Option and have either done so or knowingly and voluntarily declined to do so. Additionally, you acknowledge that
the Option is exempt from Section 409A only if the exercise price is at least equal to the “fair market value” of the
Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation
associated with the Option. Additionally, as a condition to accepting the Option, you agree not make any claim against the Company, or
any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise is less
than the “fair market value” of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.

 

10.           Severability.
If any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness
or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of
this Option Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which
will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and
valid

 

11.           Other
Documents. You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated
under the Securities Act, which includes the Prospectus. In addition, you acknowledge and agree to be subject to the Company’s Trading
Policy, which such Trading Policy has been or will be made available to you.

 

12.           Questions.
If you have questions regarding these or any other terms and conditions applicable to your Option, including a summary of the applicable
federal income tax consequences please see the Prospectus.

 

* * * *

 

    	 	5	 

     

    

 

ATTACHMENT II

 

2022 EQUITY INCENTIVE PLAN

 

    	 	 	 

     

    

 

ATTACHMENT III

 

NOTICE OF EXERCISE

 

    	 	 	 

     

    

 

NEUROBO PHARMACEUTICALS, INC.

 

(2022 EQUITY INCENTIVE PLAN)

 

NOTICE OF EXERCISE

 

NeuroBo Pharmaceuticals, Inc.

200 Berkeley Street, 19th Floor

Boston, Massachusetts 02116

Attention: Chief Executive Officer

 

Date of Exercise: _____________

 

This constitutes notice to
NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company”) that I elect to purchase the below
number of shares of the Common Stock of the Company (the “Shares”) by exercising my Option for the price set
forth below. Capitalized terms not explicitly defined in this Notice of Exercise but defined in the Grant Notice, Option Agreement or
2022 Equity Incentive Plan (the “Plan”) shall have the meanings set forth therein, as applicable. Use of certain
payment methods is subject to Company and/or Committee consent and certain additional requirements set forth in the Option Agreement and
the Plan.

 

	Type of option (check one):	 	Incentive  ̈	 	 	Nonstatutory  ̈
	Date of Grant:	 	 	 	 	 
	Number of Shares as to which Option is exercised:	 	 	 	 	 
	Certificates to be issued in name of:	 	 	 	 	 
	Total exercise price:	 	$		 	 	 
	Cash, check, bank draft or money order delivered herewith:	 	$		 	 	 
	Value of                  Shares delivered herewith:	 	$		 	 	 
	Regulation T Program (cashless exercise)	 	$		 	 	 
	Value of                  Shares pursuant to net exercise:	 	$	          	 	 	 

 

By this exercise, I agree
(i) to provide such additional documents as the Company may require pursuant to the terms of the Plan, (ii) to satisfy the tax
withholding obligations, if any, relating to the exercise of this Option as set forth in the Option Agreement, and (iii) if this
exercise relates to an incentive stock option, to notify the Company in writing within 15 days after the date of any disposition of any
of the Shares issued upon exercise of this Option that occurs within two years after the Date of Grant or within one year after such Shares
are issued upon exercise of this Option.

 

I further agree that, if required
by the Company (or a representative of the underwriters) in connection with the first underwritten registration of the offering of any
securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option
for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares
of the Common Stock or other securities of the Company for a period of one hundred eighty (180) days following the effective date
of a registration statement of the Company filed under the Securities Act (or such longer period as the underwriters or the Company shall
request to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation) (the “Lock-Up
Period”). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or
the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the
foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions
until the end of such period.

 

	 	Very truly yours,
	 	 
	 	 

 

    	 	1	 

     

    

 

Non-Employee Director

 

NEUROBO PHARMACEUTICALS, INC.

STOCK OPTION GRANT NOTICE

(2022 EQUITY INCENTIVE PLAN)

 

NeuroBo
Pharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its 2022 Equity Incentive
Plan (the “Plan”), has granted to you (“Optionholder”) an option to purchase the number
of shares of the Common Stock set forth below (the “Option”). Your Option is subject to all of the terms and
conditions as set forth in this Stock Option Grant Notice (the “Grant Notice”) and in the Plan, the Stock Option
Agreement and the Notice of Exercise, all of which are attached hereto and incorporated herein in their entirety. Capitalized terms not
explicitly defined herein but defined in the Plan or the Stock Option Agreement shall have the meanings set forth in the Plan or the Stock
Option Agreement, as applicable.

 

	 	Optionholder:		 
	 	 	 	 
	 	Date
    of Grant:		 
	 	 	 	 
	 	Number of Shares of the Common Stock
        Subject to Option:
		 
	 	 	 	 
	 	Exercise
    Price (Per Share):		 
	 	 	 	 
	 	Total
    Exercise Price:		 
	 	 	 	 
	 	Expiration
    Date:		 

 

	
    Type of Grant:

     
	
    Nonstatutory Stock Option

     

	
    Exercise and Vesting
    Schedule:
	
    Subject to the Optionholder’s Continuous
    Service through each applicable vesting date, the Option will vest as follows, subject to the potential vesting acceleration described
    in Section 2 of the Stock Option Agreement:

     

    [Initial Grant]The shares subject to the
    Option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Date
    of Grant.

     

    [Annual Grant][The shares subject to the
    Option shall vest and become exercisable on the earlier of (i) the one-year anniversary of the Date of Grant and (ii) the day
    immediately prior to the date of the Company’s next annual stockholder meeting following the Date of Grant.]

 

Optionholder
Acknowledgements: By your signature below or by electronic acceptance or authentication in a form authorized by the Company,
you understand and agree that:

 

		•	The Option is governed by this Grant Notice, and the provisions of the Plan, the Stock Option Agreement
and the Notice of Exercise, all of which are made a part of this document. Unless otherwise provided in the Plan, this Grant Notice and
the Stock Option Agreement (together, the “Option Agreement”) may not be modified, amended or revised except
in a writing signed by you and a duly authorized officer of the Company.

 

    	 	1	 

     

    

 

		•	You consent to receive this Grant Notice, the Stock Option Agreement, the Plan and any other Plan-related
documents (including the Prospectus) by electronic delivery and to participate in the Plan through an on-line or electronic system established
and maintained by the Company or another third party designated by the Company.

 

		•	You have read and are familiar with the provisions of the Plan, the Grant Notice, the Stock Option Agreement,
the Notice of Exercise and the Prospectus. In the event of any conflict between the provisions in this Grant Notice, the Option Agreement,
the Notice of Exercise, or the Prospectus and the terms of the Plan, the terms of the Plan shall control.

 

		•	The Option Agreement sets forth the entire understanding between you and the Company regarding the acquisition
of the Common Stock and supersedes all prior oral and written agreements, promises and/or representations on that subject with the exception
of other equity awards previously granted to you and any written employment agreement, offer letter, severance agreement, written severance
plan or policy, or other written agreement between the Company and you in each case that specifies the terms that should govern this Option.

 

		•	Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission
method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

	
    THE COMPANY:

     

    NeuroBo
Pharmaceuticals, Inc.
	 	
    OPTIONHOLDER:

     

	 	 	 
	By:	 	 	 
	Name:	 	 	[Insert Name]
	Title:	 	 	 
	 	 	 	 
	Date:	                                 	 	Date:	                        

  

ATTACHMENTS:
Stock Option Agreement, 2022 Equity Incentive Plan, Notice of Exercise

 

    	 	2	 

     

    

 

ATTACHMENT I

 

STOCK OPTION AGREEMENT

 

    	 	 	 

     

    

 

NEUROBO PHARMACEUTICALS, INC.

2022 EQUITY INCENTIVE PLAN

 

STOCK OPTION AGREEMENT

 

As reflected by your Stock
Option Grant Notice (the “Grant Notice”), NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company”)
has granted you an option under its 2022 Equity Incentive Plan (the “Plan”) to purchase a number of shares of
the Common Stock at the exercise price indicated in your Grant Notice (the “Option”). Capitalized terms not
explicitly defined in this Agreement but defined in the Grant Notice or the Plan shall have the meanings set forth in the Grant Notice
or Plan, as applicable. The terms of your Option as specified in the Grant Notice and this Stock Option Agreement constitute your Option
Agreement.

 

The general terms and conditions
applicable to your Option are as follows:

 

1.             Governing
Plan Document. Your Option is subject to all the provisions of the Plan, including but not limited to the provisions in:

 

(a)            Section 6
regarding the impact of a Capitalization Adjustment, dissolution, liquidation, or Corporate Transaction on your Option;

 

(b)            Section 9(e) regarding
the Company’s retained rights to terminate your Continuous Service notwithstanding the grant of the Option; and

 

(c)            Section 8
regarding the tax consequences of your Option.

 

Your Option is further subject
to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the
Plan. In the event of any conflict between the Option Agreement and the provisions of the Plan, the provisions of the Plan shall control.

 

2.             Vesting.

 

(a)            Your
Option will vest as provided in your Grant Notice, subject to the provisions contained herein and the terms of the Plan. Vesting will
cease upon the termination of your Continuous Service. Notwithstanding the foregoing, if a Change in Control occurs and your Continuous
Service has not terminated as of immediately prior to such Change in Control, then the vesting and exercisability of your Option will
be accelerated in full upon such Change in Control.

 

(b)            If
any payment or benefit you would receive from the Company or otherwise in connection with a Change in Control or other similar transaction
(a “280G Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G
of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise
Tax”), then any such 280G Payment (a “Payment”) shall be equal to the Reduced Amount. The “Reduced
Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after
reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount
(i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment
taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax
basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a
reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of
the preceding sentence, the reduction shall occur in the manner (the “Reduction Method”) that results in the
greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced
will be reduced pro rata (the “Pro Rata Reduction Method”).

 

    	 	1	 

     

    

 

Notwithstanding the foregoing,
if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to
Section 409A of the Code that would not otherwise be subject to taxes pursuant to Section 409A of the Code, then the Reduction
Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to
Section 409A of the Code as follows: (A) as a first priority, the modification shall preserve to the greatest extent possible,
the greatest economic benefit for you as determined on an after-tax basis; (B) as a second priority, Payments that are contingent
on future events (e.g., being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future
events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A
of the Code shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A
of the Code.

 

Unless you and the Company
agree on an alternative accounting firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day
prior to the effective date of the change of control transaction triggering the Payment shall perform the foregoing calculations. If the
accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the change
of control transaction, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder.
The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The Company
shall use commercially reasonable efforts to cause the accounting firm engaged to make the determinations hereunder to provide its calculations,
together with detailed supporting documentation, to you and the Company within fifteen (15) calendar days after the date on which
your right to a 280G Payment becomes reasonably likely to occur (if requested at that time by you or the Company) or such other time as
requested by you or the Company.

 

If you receive a Payment for
which the Reduced Amount was determined pursuant to clause (x) of the first paragraph of this Section 2(b) and the
Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you shall promptly return
to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 2(b))
so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined
pursuant to clause (y) in the first paragraph of this Section 2(b), you shall have no obligation to return any portion
of the Payment pursuant to the preceding sentence.

 

3.             Exercise.

 

(a)           You
may generally exercise the vested portion of your Option for whole shares of the Common Stock at any time during its term by delivery
of payment of the exercise price and applicable withholding taxes and other required documentation to the Plan Administrator in accordance
with the exercise procedures established by the Plan Administrator, which may include an electronic submission. Please review Sections
4(i), 4(j) and 7(b)(v) of the Plan, which may restrict or prohibit your ability to exercise your Option during
certain periods.

 

(b)           To
the extent permitted by Applicable Law, you may pay your Option exercise price as follows:

 

(i)            cash,
check, bank draft or money order;

 

    	 	2	 

     

    

 

(ii)            subject
to Company and/or Committee consent at the time of exercise, pursuant to a “cashless exercise” program as further described
in Section 4(c)(ii) of the Plan if at the time of exercise the Common Stock is publicly traded;

 

(iii)           subject
to Company and/or Committee consent at the time of exercise, by delivery of previously owned shares of the Common Stock as further described
in Section 4(c)(iii) of the Plan; or

 

(iv)            subject
to Company and/or Committee consent at the time of exercise by a “net exercise” arrangement as further described in Section 4(c)(iv) of
the Plan.

 

4.             Term.
You may not exercise your Option before the commencement of its term or after its term expires. The term of your Option commences on the
Date of Grant and expires upon the earliest of the following:

 

(a)            immediately
upon the termination of your Continuous Service for Cause;

 

(b)            12
months after the termination of your Continuous Service for any reason other than Cause or death;

 

(c)            18
months after your death if you die during your Continuous Service;

 

(d)            immediately
upon a Corporate Transaction if the Board has determined that the Option will terminate in connection with a Corporate Transaction;

 

(e)            the
Expiration Date indicated in your Grant Notice; or

 

(f)            the
day before the 10th anniversary of the Date of Grant.

 

Notwithstanding the foregoing,
if you die during the period provided in Section 4(b) above, the term of your Option shall not expire until the earlier
of (i) 18 months after your death, (ii) upon any termination of the Option in connection with a Corporate Transaction, (iii) the
Expiration Date indicated in your Grant Notice, or (iv) the day before the tenth anniversary of the Date of Grant. Additionally,
the Post-Termination Exercise Period of your Option may be extended as provided in Section 4(i) of the Plan.

 

5.             Withholding
Obligations.  As further provided in Section 8 of the Plan: (a) you may not exercise your Option unless the
applicable tax withholding obligations are satisfied, and (b) at the time you exercise your Option, in whole or in part, or at any
time thereafter as requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise
agree to make adequate provision for (including by means of a “cashless exercise” pursuant to a program developed under Regulation
T as promulgated by the Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state,
local and foreign tax withholding obligations, if any, which arise in connection with the exercise of your Option in accordance with the
withholding procedures established by the Company. Accordingly, you may not be able to exercise your Option even though the Option is
vested, and the Company shall have no obligation to issue shares of the Common Stock subject to your Option, unless and until such obligations
are satisfied. In the event that the amount of the Company’s withholding obligation in connection with your Option was greater than
the amount actually withheld by the Company, you agree to indemnify and hold the Company harmless from any failure by the Company to withhold
the proper amount.

 

    	 	3	 

     

    

 

6.             Transferability.
 Except as otherwise provided in Section 4(e) of the Plan, your Option is not transferable, except by will or by
the applicable laws of descent and distribution, and is exercisable during your life only by you.

 

7.             Corporate
Transaction. Your Option is subject to the terms of any agreement governing a Corporate Transaction involving the Company,
including, without limitation, a provision for the appointment of a stockholder representative that is authorized to act on your behalf
with respect to any escrow, indemnities and any contingent consideration.

 

8.            No
Liability for Taxes. As a condition to accepting the Option, you hereby (a) agree to not make any claim against the Company,
or any of its Officers, Directors, Employees or Affiliates related to tax liabilities arising from the Option or other Company compensation
and (b) acknowledge that you were advised to consult with your own personal tax, financial and other legal advisors regarding the
tax consequences of the Option and have either done so or knowingly and voluntarily declined to do so. Additionally, you acknowledge that
the Option is exempt from Section 409A only if the exercise price is at least equal to the “fair market value” of the
Common Stock on the date of grant as determined by the Internal Revenue Service and there is no other impermissible deferral of compensation
associated with the Option. Additionally, as a condition to accepting the Option, you agree not make any claim against the Company, or
any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that such exercise is less
than the “fair market value” of the Common Stock on the date of grant as subsequently determined by the Internal Revenue Service.

 

9.             Severability.
If any part of this Option Agreement or the Plan is declared by any court or governmental authority to be unlawful or invalid, such unlawfulness
or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of
this Option Agreement (or part of such a Section) so declared to be unlawful or invalid will, if possible, be construed in a manner which
will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and
valid

 

10.           Other
Documents. You hereby acknowledge receipt of or the right to receive a document providing the information required by Rule 428(b)(1) promulgated
under the Securities Act, which includes the Prospectus. In addition, you acknowledge and agree to be subject to the Company’s Trading
Policy, which such Trading Policy has been or will be made available to you.

 

11.           Questions.
 If you have questions regarding these or any other terms and conditions applicable to your Option, including a summary of the applicable
federal income tax consequences please see the Prospectus.

 

* * * *

 

    	 	4	 

     

    

 

ATTACHMENT II

2022 EQUITY INCENTIVE PLAN

 

    	 	 	 

     

    

 

ATTACHMENT III

NOTICE OF EXERCISE

 

    	 	 	 

     

    

 

NEUROBO PHARMACEUTICALS, INC.

 

(2022 EQUITY INCENTIVE PLAN)

 

NOTICE OF EXERCISE

 

NeuroBo Pharmaceuticals, Inc.

200 Berkeley Street, 19th Floor

Boston, Massachusetts 02116

Attention: Chief Executive Officer

 

Date of Exercise: ________________

 

This constitutes notice to
NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company”) that I elect to purchase the below
number of shares of the Common Stock of the Company (the “Shares”) by exercising my Option for the price set
forth below. Capitalized terms not explicitly defined in this Notice of Exercise but defined in the Grant Notice, Option Agreement or
2022 Equity Incentive Plan (the “Plan”) shall have the meanings set forth therein, as applicable. Use of certain
payment methods is subject to Company and/or Committee consent and certain additional requirements set forth in the Option Agreement and
the Plan.

 

	Type of option:	 	Nonstatutory	 
	Date of Grant:	 	 	 
	Number of Shares as to which Option is exercised:	 	 	 
	Certificates to be issued in name of:	 	 	 
	Total exercise price:	 	$		 
	Cash, check, bank draft or money order delivered herewith:	 	$		 
	Value of                  Shares delivered herewith:	 	$		 
	Regulation T Program (cashless exercise):	 	$		 
	Value of                  Shares pursuant to net exercise:	 	$	          	 

 

By this exercise, I agree
(i) to provide such additional documents as the Company may require pursuant to the terms of the Plan and (ii) to satisfy the
tax withholding obligations, if any, relating to the exercise of this Option as set forth in the Option Agreement.

 

	 	Very truly yours,

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]